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Summary 
 
Application of molecular fingerprinting highlights transmission as the driving force behind the 
drug resistant epidemic in South Africa. Different strains dominate within different geographical 
regions, which is a reflection of micro-epidemics of drug resistance in the different regions. 
Cluster analysis shows that strains within the same strain family are different. The Beijing drug 
resistant strain family is the most dominant strain family (31%) in the Western Cape and of 
particular concern is the highly transmissible Beijing cluster 220 strain in the Western Cape 
communities. This cluster is widespread in the region and was previously identified in a MDR 
outbreak in a high school in Cape Town. Results suggest that the spread of Beijing drug resistant 
cluster 220 in the community was due to a combination of acquisition of drug resistant markers 
and transmission. This study also indicate that atypical Beijing can acquire drug resistance and 
become fit amongst HIV infected individuals. This is contrary to believe that atypical Beijing 
strains are not frequently associated with drug resistance and are attenuated. This implies that 
HIV levels the playing field for all drug resistant strains.  
 
Mechanisms leading to the evolution of MDR-TB and XDR-TB in a mine setting with a well-
functioning TB control program which exceeds the target for cure rates set by the WHO were 
investigated. Despite the excellent control program, an alarming increase in the number of drug 
resistant cases was observed in 2003 and subsequent years. Phylogenetic analysis shows 
sequential acquisition of resistance to first and second-line anti-TB drugs leading to the 
development of MDR and XDR-TB. Contact tracing indicate extensive transmission of drug 
resistant TB in the shafts, hospital and place of residence.  This study shows that despite 
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exceeding the WHO cure rate target, it was not possible to control the spread and amplification 
of drug resistance. In summary, as a top priority, future TB control plans need to address 
diagnostic delay more vigorously. 
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Opsomming 
 
Molukulêre tegnieke toon transmissie as die hoofrede vir die toename in die anti-tuberkulose 
middelweerstandigheid epidemie in Suid-Afrika. Die verskillende Mikobakterium tuberkulose 
rasse wat domineer in verskillende areas is ‘n refleksie van middelweerstandige mikro-epidemies 
in verskillende gebiede. Analise van identiese rasgroepe demonstreer dat ras families bestaan uit 
verskillende rasse. Die Beijing middelweerstandige rasfamilie is die mees dominante familie in 
die Wes-Kaap (31% van monsters van middelweerstandige families) en van spesifieke belang is 
die hoogs oordraagbare Beijing 220 groep. Hierdie groep is die mees wydverspreide groep in die 
studie area en was voorheen geïdentifiseer tydens ‘n meervoudige middelweerstandige 
uitbreking in ‘n hoërskool in Kaapstad. Die resultate dui aan dat die Beijing middelweerstandige 
groep 220 in die gemeenskap versprei as gevolg van ‘n kombinasie van middelweerstand 
verwerwing en transmissie. Hierdie studie dui verder aan dat die atipiese Beijing ook 
middelweerstandigheid kan verwerf en hoogs geskik is vir infeksie veral in MIV geïnfekteerde 
individue. Hierdie data is in teenstelling met die algemene denke dat atipiese Beijing nie gereeld 
geassosieer word met middelweerstandigheid nie en dat dit dikwels geattenueer is. Dit beteken 
dat MIV die hoof faktor is wat alle middelweerstandige rasse kans gee om te versprei. 
 
Hierdie studie het die meganisme wat lei tot die evolusie van middelweerstandigheid en “XDR-
TB” in die myne ondersoek. Die myn besit ‘n goeie funksioneerde tuberkulose kontrole program 
wat alreeds die Wêreld Gesondheids Organisasie se mikpunt vir tuberkulose genesing oortref. 
Ten spyte van ‘n uitstekende tuberkulose kontrole program, is daar ‘n bekommerenswaardige 
toename in die aantal middelweerstandige tuberkulose gevalle waargeneem in 2003 en in die 
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daaropvolgende jare. Filogenetiese analise wys dat opeenvolgende verwerwing van 
middelweerstandigheid teen eerste en tweede vlak anti-tuberkulose middels gelei het tot die 
ontwikkeling van meervoudige middelweerstandigheid en “XDR-TB”. Die opsporing van 
kontakpersone om transmissie te bewys dui aan dat transmissie van middelweerstandige 
tuberkulose in die werk plek, hospitaal en woon plek plaasvind. Hierdie studie wys dat ongeag 
die feit dat die Wêreld Gesondheids Organisasie se genesings verwagtinge oortref is, dit steeds 
onmoontlik was om die verspreiding en amplifisering van middelweerstandigheid te beheer. ‘n 
Top prioriteit vir tuberkulose kontrole planne in die toekoms behoort die vertraging van diagnose 
sterk aan te spreek.  
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Chapter 1 
 
The role of IS6110 in the evolution of Mycobacterium 
tuberculosis. 
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published in the journal, Tuberculosis, September 2007, Volume 87, Issue 5, pages 
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1. Introduction 
 
Mycobacterium tuberculosis (M.tuberculosis) is the causative agent of tuberculosis (TB), 
a respiratory disease responsible for over 2 million deaths annually, with an estimated 
one third of the world’s population being latently infected (13). In industrialised countries 
the TB infection rate has decreased due to the availability of effective drugs as well as 
improved socio-economic conditions. However, poor public health systems in developing 
countries, the HIV/AIDS pandemic, and the emergence of multi-drug resistant (MDR) 
strains, have contributed to an ongoing increase in reported cases worldwide (19). 
 
One of the main aspects of TB research is the epidemiology of M.tuberculosis, with the 
aim to document the disease dynamics in different groups of individuals (11). This will 
enable the epidemiologist to deduce the reason for the disease occurring in a particular 
setting. In recent years, molecular epidemiological methods have been used extensively 
in transmission studies of M.tuberculosis. With the release of the M.tuberculosis genome 
(12) our knowledge of this organism has increased significantly and we can now focus on 
its evolution and genetics. M.tuberculosis is one member of the M.tuberculosis complex 
(MTBC), which consists of M.tuberculosis, M.bovis, M.africanum, M.pinnipedii, 
M.caprae, M.microti and M.canetti. The members are closely related, demonstrated by 
the high (99.9%) sequence similarity on the nucleotide level (44), which may have 
resulted due to a recent evolutionary bottleneck. Although high genetic homogeneity 
between these members is evident, they all exhibit different phenotypes, induce different 
pathologies and demonstrate different host specificities. The exact evolutionary origin of 
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M.tuberculosis is still unknown but previously it has been suggested that it derived from 
M.bovis (an organism infecting cattle) as a result of a cross-species jump (45). However, 
new evidence (27,39) suggest that M.bovis derived from M.tuberculosis.  
 
1.1. Polymorphisms in M.tuberculosis genome used as genetic markers in TB 
epidemiology  
 
Approximately a decade ago, the only molecular markers available to study the 
epidemiology of TB were drug susceptibility profiles and phage types. However, there 
were some limitations to these methods and in recent years, numerous genotyping 
methods have been developed based on DNA polymorphisms in the genome of the 
organism. The discovery of polymorphic regions within the genome has led to a whole 
new era of epidemiology based on molecular methods using these polymorphic regions as 
markers. These polymorphisms are generally found in non-coding regions with different 
frequencies demonstrated between different strain families. Thus, molecular 
epidemiology of M.tuberculosis utilizes specific genetic markers within the 
M.tuberculosis genome to study the distribution of M.tuberculosis strains as well as how 
the strain distribution changes over a period of time. Molecular methods are more 
informative than traditional methods and due to the rapidity of certain molecular 
methods, it is suitable for use in TB diagnosis.  
For epidemiological studies, it is important that the marker chosen for a specific method 
must be suitable for the study setting. In the following pages some of the more common 
molecular methods used in the study of M.tuberculosis epidemiology are discussed. 
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1.2. Molecular Methods currently used in TB epidemiology 
 
1.2.1. IS6110 RFLP Analysis 
 
In 1990, Thierry et al (49) described a 1.36 kb insertion sequence (IS), which is only 
found within the MTBC. This sequence termed, (IS) 6110, belongs to the IS3 family and 
is characterised by unique 28 bp imperfect terminal inverted repeats (TIRs). IS6110 
possesses a transposase that enable it to extract itself from the genome and re-insert into 
another genomic region and is also capable of copying itself for insertion at another 
position. This ability of the sequence to frequently ‘jump’ from one location to another 
result in IS6110 displaying positional as well as numerical polymorphisms. Restriction 
fragment length polymorphism (RFLP) is a method based on this feature of IS6110, 
which is an extremely laborious and time-consuming technique. The start point for RFLP 
is bacterial growth on a specific medium, Lowenstein Jensen slant, for sufficient DNA to 
fingerprint. Restriction endonuclease, PvuII, cuts the DNA, which is then redissolved for 
gel electrophoresis to separate the cleaved DNA. This is followed by southern transfer of 
DNA to a specialized membrane followed by detection and visualization of RFLP 
patterns by autoradiography. The DNA bands represent the IS6110 insertion elements 
within the genome of different isolates of M.tuberculosis (fig.1). 
 
As a rule, transposition events of IS6110 are common enough to allow differentiation 
between more distantly evolved strains but are still rare enough to show stability within 
more closely related strains. Therefore, this method does not only differentiate between 
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strains but can determine whether epidemiological events were either recent 
(transmission) or distant (reactivation). Generally, recent transmission is expressed as a 
cluster (fig. 1, lanes 2 and 3), which is defined as two or more isolates demonstrating 
identical or related IS6110 fingerprints. The varying rates at which different IS6110 
elements transpose may have important implications for the interpretation of 
epidemiological results and highlights the fact that a more thorough knowledge of the 
biology of IS6110 and its relation to the emergence of specific M. tuberculosis strains is 
needed (16). 
 
The use of this DNA fingerprinting method has proved to be crucial in distinguishing 
between endogenous reactivation and exogenous re-infection (25), detecting outbreaks in 
hospitals (14,20,38), in prisons (52), among health care workers (4,29) and within 
communities (55). Even though the standardized IS6110 fingerprinting method (53) is the 
most widely used genotyping method in molecular epidemiological studies of M. 
tuberculosis due to its high discriminatory power, it has its shortcomings. This includes 
the laborious workload and the need for culture growth on Lowenstein-Jensen (LJ) slants 
of up to 4-6 weeks. Therefore, this method may not be suitable for diagnostic use since it 
may contribute to diagnostic delay and subsequently, treatment delay; however, it is 
suitable for an epidemiological research. Another shortcoming of this method is that 
discrimination is much lower for strains with <5 IS6110 copy numbers (low copy number 
strains) than strains with >5 IS6110 copy numbers (high copy number strains). Low copy 
number strains are evolutionary stable with regard to IS6110 transposition and are less 
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likely to exhibit evolving RFLP patterns. Thus, for low copy strains, other genotyping 
methods are preferred.  
 
1.2.2. PGRS-RFLP 
 
The polymorphic GC-rich Repetitive Sequence (PGRS) is a 96bp consensus sequence 
found in the M.tuberculosis genome. The technique used is similar to IS6110 RFLP, thus 
it is time consuming and the workload is laborious. Like IS6110 RFLP, it is also based on 
the number and position of these sequences in the genome and can be used to distinguish 
between low copy number strains (10). Unfortunately due to the complex fingerprints (as 
a result of the high frequency of PGRS copies in the genome), reproducibility and 
analysis of these fingerprints is extremely difficult (35). Therefore, the use of this method 
is restricted. 
 
1.2.3. Spoligotyping 
 
This DNA amplification-based typing technique is more rapid than RFLP and is also 
capable of detecting and typing M.tuberculosis in clinical specimens (24,31). A 
polymorphic region, containing numerous well-conserved 36-bp direct repeats (DRs) is 
unique in MTBC bacteria. These loci are interspersed with 34 - 41 bp long unique non-
repetitive spacer sequences, which can be amplified through PCR using primers designed 
from the DR sequence (fig 2) (26). A single DR region along with the adjacent spacer is 
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known as the Direct Variable Repeat (DVR). The first step in this methodology is PCR 
amplification of the DR region. This is followed by linkage of synthetic oligonucleotides, 
specific to each spacer, to an activated membrane in parallel lines. The PCR products are 
then hybridised perpendicular to the oligo lines, which can be visualised using 
chemoluminescence and autoradiography. Differentiation between M.tuberculosis 
isolates depend on the presence or absence of the spacer sequences (fig 3) (31). 
 
It has been demonstrated that spoligotyping can aid in distinguishing whether a particular 
TB episode is due to relapse or re-infection (58). Except for the reproducibility of this 
method, other advantages of spoligotyping is its high throughput and that data can be 
easily compared between laboratories. The discriminative power of this method however, 
is much lower than RFLP (24), which means that the use of this method alone can lead to 
an overestimation of true transmission. An example is the Beijing/W lineage, which has 
earned a lot of attention based on its ability to frequently cause outbreaks (5). It consists 
of numerous families and can be subdivided into multiple strains using IS6110 RFLP and 
MIRU-VNTR markers (40). However, the genotype of the Beijing strain remains 
identical when using the spoligotyping method. 
 
According to the Centres of Disease Control (CDC) TB laboratory procedures, results of 
spoligotyping must be given as an octal code designation with a binary conversion as an 
intermediate (fig.4). This is to simplify the recording of spoligotypes and the report of 
results from genotyping laboratories to TB programs. 
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1.2.4. MIRU-VNTR Analysis 
 
Due to the time consuming factor of RFLP and the low discriminatory power of 
spoligotyping compared to RFLP, a new method has been developed, which may provide 
a viable alternative. Mycobacterial interspersed repetitive units (MIRUs) are 40-100 bp 
long minisatellite-like structures that were identified within the M.tuberculosis genome 
and were found to be located at 41 locations within the H37Rv genome (47). The 
polymorphisms within certain locations enable the differentiation of M.tuberculosis 
strains since MIRU copy number differences are evident between non-related 
M.tuberculosis isolates, therefore this genotyping method is based on the variable 
numbers of tandem repeats (VNTRs) of MIRUs (21,34). With this method, different sets 
of loci can be used for strain typing depending on the strain population. Currently, the 
system based on the 12 set loci is the most widely used (36,48). Other loci sets proposed 
for use in routine epidemiological analysis are the 15 loci set with discrimination equal to 
RFLP as well as the 9 loci set.  
 
This technique is PCR based so it is rapid, it has a high throughput (2) and its output or 
the MIRU type is expressed as a 12 digit code (depending on the loci set used) (fig.5). 
This code can be analyzed and it facilitates exchange of data between laboratories (17). 
 
MIRU-VNTR can be used as a tool to study the evolution of the M.tuberculosis genome 
(47). MIRUs are also a suitable marker for transmission studies in high incidence settings 
where clustering may be over represented. 
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As described previously, a numbering system is used in the analysis of different MIRU 
strain types. Currently, these following 12 set loci are frequently used: 02, 04, 10, 16, 20, 
23, 24, 26, 27, 31, 39 and 40. Each number in the 12 character designated code represents 
the number of repeats at each MIRU loci. If the number of repeats exceeds 9, a letter is 
incorporated in the code to avoid the use of double-digit numbers, e.g. 10 repeats = “a”, 
11 repeats = “b”, etc. Occasionally, no repeats are present at any one of the MIRU loci, 
which is represented with a “0” and regions that are deleted are indicated by a dash (-). 
 
1.2.5. Other PCR-based methods 
 
Due to the limitations of IS6110 RFLP, another rapid method based on PCR 
amplification was developed. Fast Ligation-Mediated PCR is an easily reproducible (33) 
method with discriminatory power that is slightly less than IS6110 RFLP. However, the 
method is limited to genotyping high copy number strains as the same principle applied 
to IS6110 RFLP is applied here. Clusters that are of epidemiological interest may contain 
specific polymorphisms that can be used for screening purposes by PCR, which is much 
more rapid than RFLP fingerprinting.  
 
Recently, a study (30) documented transmission of the drug resistant Beijing cluster 220 
strain in the Western Cape region. In this paper, a novel PCR based method (fig.6) was 
described, which amplified a genomic region that was specific to this cluster. When the 
results obtained from the PCR-based method were compared to the IS6110 RFLP 
fingerprint patterns of cluster 220 patients, it was found that the results correlated well. 
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Similarly, sequences that are specific to mycobacterium species can also be amplified 
through PCR as shown in figure 7 (57). The method is useful in studies showing the 
evolutionary pathway of mycobacterial species based on specific genomic deletions.  
 
Today, molecular methods are increasingly applied to the control of TB and more 
methods are developed as more information on the M.tuberculosis genome becomes 
available. As a consequence, molecular methods have become an extremely valuable tool 
in the detection of drug resistance and in the understanding of the transmission dynamics 
of different M.tuberculosis strains including those that possess drug resistance.  
 
1.3. Comparative Strain Analysis based upon DNA Fingerprinting Methods (Databases) 
 
We have established a comprehensive RFLP database using the GelCompar II analysis 
software, which contain fingerprints of 4209 isolates taken from 2034 drug susceptible 
and drug resistant patients between January 1993-December 2004. During this time, 700 
strains have been identified. With this program, it is possible to calculate the similarity 
between fingerprints of study samples based on mathematical algorithms, which will 
generate groupings of similar fingerprint patterns.  
The international spoligotype database, SpolDB4, contain spoligopatterns of isolates 
collected globally (6). Our local spoligotype database is a collection of 7053 isolates 
obtained from various regions locally as well as globally. Strains that are new to the 
database (i.e. not previously identified) can be compared to strains within the SpolDB4 
database and entered into the local database. As a result, these databases are updated 
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regularly and are linked to a collective database containing clinical as well as socio-
economic data of patients (treated as confidential) for research purposes 
 
1.4. TB Control  
 
In 1991, the World Health Organization (WHO) recommended an innovative strategy for 
the control of TB, called the Direct Observed Treatment Short-course (DOTS) program. 
In 1996, the DOTS program was implemented in South Africa and since then successful 
treatment rates have increased yet still remains low at 70% in 2004 (62). The DOTS 
strategy is built on the five following elements: 
 
• Political commitment to effective TB control. 
• Case detection by sputum smear microscopy among symptomatic people. 
• Standardized treatment regimen of 6-8 months of short-course chemotherapy 
(SCC) with first-line anti-TB drugs, administered under proper case management 
conditions, including direct observation. 
• Uninterrupted supply of all essential anti-TB drugs. 
• Standardized recording and reporting system, allowing assessment of treatment 
results. 
 
The DOTS strategy is the first line of defends against drug resistant TB. Patients that are 
drug susceptible can be cured in six to eight months with the first-line anti-TB drugs: 
isoniazid (INH), rifampicin (RIF), ethambutol (Emb), pyrazinamide (PZA) and 
Stellenbosch University  http://scholar.sun.ac.za
 12
streptomycin (Sm). Different levels of drug resistance exist, depending on the quantity 
and class of drugs to which an M.tuberculosis isolate demonstrates resistance. Multiple 
drug resistance implies M.tuberculosis, which shows resistance to more than one anti-TB 
drug. Multi-drug resistance (MDR) is defined as M.tuberculosis resistant to two of the 
most important first-line anti-TB drugs, RIF and INH. The standard MDR-TB treatment 
consists of second-line anti-TB drugs, since the first-line drugs, RIF and INH, are 
ineffective. Currently, it is estimated that more than 6000 new MDR-TB cases are 
diagnosed in the country each year (61). 
 
Drug resistant TB is a man-made problem and is found globally (61). Drug resistance 
mainly develop through the improper use of antibiotics by drug-susceptible TB patients 
(60), which can then spread to secondary cases. This improper use includes, 
administration of improper treatment regimens by health care workers and failure to 
ensure that patients complete the whole course of treatment (15). The management 
initiative, DOTS-Plus is a strategy based upon the five elements of the DOTS program 
with the aim to prevent the further development and spread of MDR-TB. The DOTS-Plus 
strategy is only administered in selective regions where drug resistance has been 
observed with the priority to increase access to second-line anti-TB drugs especially in 
middle- and low- income countries. 
 
The mechanism by which drug resistance emerges is through the sequential acquisition of 
mutations. Initially, a spontaneous mutation causes one organism to become naturally 
resistant to anti-tuberculosis drugs. Due to a selection process, such as a non-compliant 
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patient, an overgrowth of the resistant population, containing the initial specific mutation, 
occurs. Subsequently, selection of sub-populations carrying these mutations conferring 
drug resistance may occur (43), which is known as “acquired” drug resistance. Therefore, 
the defining criterion of acquired drug resistance according to the WHO is that a patient 
with drug resistant TB has been treated one month or longer (1). In contrast, “primary 
resistance” is an indication of drug resistance in a new patient that had no previous 
treatment. Surveys have shown that drug resistance due to acquisition  are more common 
than primary drug resistance (41). In the Western Cape however, we have found that 
most MDR epidemics was due to transmission (56). Van Rie et al (2000)(54) reported 
that clinical classification of drug resistant patients (patients that were previously treated) 
alone may be insufficient in interpreting drug resistant epidemics. With RFLP analysis, 
the study revealed that MDR strains were actually transmitted between patients that were 
previously treated. Therefore, it was suggested that acquired resistance be re-defined as 
“drug resistance in previously treated cases”, which would include cases in which drug 
resistance was truly acquired and cases through which drug resistance was transmitted. 
 
Extreme Drug Resistant TB (XDR-TB) has recently emerged and has been defined as 
MDR-TB with additional resistance demonstrated to the second-line drugs; a 
Fluoroquinolone and one or more of the three injectable drugs Kanamycin (K), Amikacin 
(Am), and Capreomycin (C) (9). A joint global survey by the World Health Organization 
(WHO) and the Centres for Disease Control (CDC) identified XDR-TB in all regions of 
the world, thereby recognising this as a new threat to TB control (9). The first reported 
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incidence of XDR-TB in South Africa was in Tugela Ferry, KwaZulu-Natal, where 52 
immunocompromised TB patients died (23).  
 
Despite efforts by DOTS-Plus program to treat and prevent the spread of drug resistance, 
the problem of MDR and XDR-TB has now become a global threat including in South 
Africa. The HIV epidemic exacerbates drug resistance since it leads to rapid disease 
progression in HIV-seropositive cases. Both MDR-TB (7) and XDR-TB (23), have been 
associated with HIV. However, there have also been reports demonstrating MDR-TB and 
XDR-TB being diagnosed among HIV-seronegative cases (55)(our unpublished data. 
“Emergence of XDR-TB in a South African gold mine”-Chapter 3). Therefore, as the 
precursor of XDR-TB, the management of MDR-TB must be re-evaluated since it is 
likely that wherever second-line anti-TB drugs are administered, XDR-TB may evolve. 
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1.5. Molecular Biological Methods used for detection of Drug Resistance 
 
In the past, susceptibility to anti-TB drugs relied on classical methods based on bacilli 
growth on culture media, often resulting in treatment delay. Therefore, rapid diagnosis of 
drug resistant as well as susceptible TB is an essential part in the control of TB. However, 
such methods must be cost effective especially for resource poor countries. PCR 
amplification based methods are fast and efficient and will shorten the delay period. Most 
cases of drug resistance are caused by known mutations in a specific gene that is 
associated with resistance to anti-TB drugs. This makes it relatively easy to detect these 
mutations by PCR amplification followed by sequencing (51). Indeed, Sekiguchi et al 
(2007) (42) demonstrated that the amount of time in which PCR followed by sequencing 
could be accomplished, was 6.5 hours. Real-time PCR is an easy and specific method 
used to screen for drug resistance. However, since probes are designed for specific 
mutations, some resistant isolates may be missed. This problem can be circumvented by 
using molecular methods in conjunction with classical culture methods (32). 
 
Since MDR as well as XDR are important concerns for the clinician, early detection of 
drug resistance can be the most crucial tool in saving lives of those suspected of being 
infected. In settings with high MDR prevalence, detection of RIF resistance can be useful 
because in most instances RIF resistance is accompanied by INH resistance, i.e. it acts as 
a good indicator of MDR (22,50,59). Thus, early detection of RIF resistance as well as 
resistance to any other anti-TB drugs may be vital for a good TB control strategy. As 
mentioned above, amplification and sequencing of the gene, rpoB, which is associated 
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with RIF resistance is a relatively easy and rapid method to use for detecting RIF 
resistance. Another, molecular test known as INNO-LiPA.Rif TB (Innogenetics, 
Belgium), rapidly detects RIF resistance within 2 days while simultaneously detecting 
M.tuberculosis in clinical specimens, therefore no culture is needed (51). This method 
has a high specificity however; the high cost of this test make it unsuitable for resource 
poor countries. The rapid diagnostic test, the Genotype MTBDR assay shows promise 
however, conventional drug susceptibility testing must be used in conjunction since not 
all mutations that confer resistance can be detected by this assay (28). The microscopic-
observation drug susceptibility (MODS) assay detects both TB and MDR-TB directly 
from sputum with high specificity as well as more speed and reliability than identification 
using conventional methods (37).  
Other method for detecting RIF resistance include heteroduplex analysis and single-
stranded conformational polymorphism (SSCP) analysis but both these methods are 
cumbersome. One rapid, low cost method for detecting RIF resistant isolates is the 
microarray (8), which proved also useful as a screening tool for PZA resistance (18).  
 
Genotyping methods are not used as a substitute for classical methods but rather these 
methods combined ensure rapid results and confirmation of drug susceptibility. 
Population-based genotyping studies indicate that some strains are more easily 
transmitted than other strains. Outbreak strains may thus have specific characteristics that 
make them more predisposed to transmit more frequently. With molecular 
epidemiological studies, it has been determined that most MDR-TB cases in the Western 
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Cape region were due to transmission (56). Today, numerous micro-epidemics, as a result 
of MDR-TB transmission, are occurring throughout local communities (46,54,55), 
highlighting the need to be more vigilant in settings of high drug resistance and the need 
for better TB control strategies.  
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Fig 1.: Autoradiograph of IS6110 DNA patterns of different M.tuberculosis isolates. 
Legend: Each lane represent an M.tuberculosis isolate and each DNA band represents an IS6110 copy. 
Lanes 2 and 3, from two different cases, are identical strains and are thus considered clustered. Unrelated 
strains will have different DNA patterns, for example, lanes 5 and 6. Lane 1 is the standard laboratory 
strain, M.tuberculosis 14323. 
 
Lanes 1  2  3  4  5  6
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Fig.2: Schematic view of DR regions and spoligotyping. 
Legend: A) The structure of the DR locus in genomes of H37rv (top) and BCG (bottom). B) In vitro 
amplification of DNA between the DR regions. Primers synthesized specifically for the DR regions, 
amplify the sequence spacers in between. The resultant PCR products differ in length based on two points 
1) the product contains several spacers and the DRs in between, if the primers anneal to DR’s not next to 
each other, and 2) the product itself can act as a primer, and become elongated with one or more DVR’s.  
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Fig 3.: Spoligotype patterns of drug resistant M. tuberculosis isolates from two health districts in the 
Western Cape, South Africa (46).  
Legend: The black area within the fingerprint represents the presence of a spacer sequence and the blanks 
represent the absence of the spacers 
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Fig 4.: Conversion of spacer sequences to an octal code. 
Legend: The binary code is reverted to an octal designation by way of a two-step process. 1) The binary 
code is divided into 14 sets of three digits with an extra digit. 2) Each three digit code is converted to an 
octal code, while the extra digit remain as either 1 or 0. The octal designation for each different three digits 
is: 000 = 0; 001 = 1; 010 = 2; 011 = 3; 100 = 4; 101 = 5; 110 = 6; and 111 = 7. 
 
 
 
 
 
 
 
 
1 43
Original banding pattern
Binary code
14+1 grouping
Octal designation
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Fig 5.: Results of a study to investigate the validity of MIRU-VNTR in the classification of M.bovis using the 29 
MIRU-VNTR loci set.  
Legend: The three DNA fingerprint methods; A) IS6110 RFLP, B) spoligotyping and C) MIRU-VNTR was used to 
analyze M.bovis isolates collected from cattle. UPGMA algorithm was used to build the dendogram on the extreme 
left, which is based upon the MIRU-VNTR profiles (on the extreme right). This dendogram show five distinct 
clusters among animals from different farms all with definite epidemiological links (3).  
 
 A B                                   C
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Fig 6.: M.tuberculosis strains belonging to the Beijing family amplified by PCR. 
Legend: Cluster 220; lanes 1-4. Cluster 208; lane 5. H37Rv control; lane 6. Molecular marker; lane 8 (30).  
 
 
 
Fig 7.: Species-specific sequences differentiate between species and are often used to phylogenetically group 
them together. 
Legend: Lanes 1 to 8 are M.canetti, M.tuberculosis, M.africanum, M.microti, M.pinnepedii, M.caprae, 
M.bovis, M.bovis BCG and lane 9, negative control. Lane M is the molecular weight marker. Within lane 1, 
no band for RD12 is visible since this region is deleted in M.canetti (57). 
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Problem Statement 
Little is known about the population structure of drug resistant Mycobacterium tuberculosis 
strains in South Africa. 
 
Hypothesis 
Application of molecular epidemiological methods will aid to understand what drives the 
drug resistant epidemic in South Africa. 
 
Aim of the study 
To use molecular methods to investigate the population structure of drug resistant 
M.tuberculosis isolates from different regions in South Africa. 
 
Experimental Approach 
Sputum specimens will be collected from different geographical regions in South Africa. 
These isolates will be characterized by IS6110 restriction fragment length polymorphism 
(RFLP), spoligotyping and/or MIRU typing as well as drug resistant genotyping (only if 
stated). Strain comparison using the international SpolDB4 database will be used to 
identify new spoligopatterns whereas IS6110 RFLP patterns will be entered into a local 
Gelcompar II database for analysis. IS6110 RFLP will be used as a secondary typing 
method to determine the clonal spread of certain strains thereby investigating transmission 
dynamics of drug resistant M.tuberculosis. 
 
Stellenbosch University  http://scholar.sun.ac.za
 25
 
Reference List 
 
 1.  1998. Guidelines for surveillance of drug resistance in tuberculosis. WHO 
Geneva/IUATLD Paris. International Union Against Tuberculosis and Lung Disease. 
Int.J.Tuberc.Lung Dis. 2:72-89. 
 2.  Allix, C., P. Supply, and M. Fauville-Dufaux. 2004. Utility of fast mycobacterial 
interspersed repetitive unit-variable number tandem repeat genotyping in clinical 
mycobacteriological analysis. Clin.Infect.Dis. 39:783-789. 
 3.  Allix, C., K. Walravens, Saegerman c, J. Godfroid, P. Supply, and M. Fauville-
Dufaux. 2006. Evaluation of the epidemiological relevance of variable-number 
tandem-repeat genotyping of Mycobacterium bovis and comparison of the method 
with IS6110 restriction fragment length polymorphism analysis and spoligotyping. 
J.Clin.Microbiol. 44:1951-1962. 
 4.  Beck-Sague, C., S. W. Dooley, M. D. Hutton, J. Otten, A. Breeden, J. T. Crawford, 
A. E. Pitchenik, C. Woodley, G. Cauthen, and W. R. Jarvis. 1992. Hospital outbreak 
of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission 
to staff and HIV-infected patients. JAMA 268:1280-1286. 
 5.  Bifani, P. J., B. Mathema, N. E. Kurepina, and B. N. Kreiswirth. 2002. Global 
dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends 
Microbiol. 10:45-52. 
Stellenbosch University  http://scholar.sun.ac.za
 26
 6.  Brudey, K., J. R. Driscoll, L. Rigouts, W. M. Prodinger, A. Gori, S. A. Al Hajoj, C. 
Allix, L. Aristimuno, J. Arora, V. Baumanis, L. Binder, P. Cafrune, A. Cataldi, S. 
Cheong, R. Diel, C. Ellermeier, J. T. Evans, M. Fauville-Dufaux, S. Ferdinand, d. 
Garcia, V, C. Garzelli, L. Gazzola, H. M. Gomes, M. C. Gutierrez, P. M. Hawkey, P. 
D. van Helden, G. V. Kadival, B. N. Kreiswirth, K. Kremer, M. Kubin, S. P. 
Kulkarni, B. Liens, T. Lillebaek, H. M. Ly, C. Martin, C. Martin, I. Mokrousov, O. 
Narvskaia, Y. F. Ngeow, L. Naumann, S. Niemann, I. Parwati, M. Z. Rahim, V. 
Rasolofo-Razanamparany, T. Rasolonavalona, M. L. Rossetti, S. Rusch-Gerdes, A. 
Sajduda, S. Samper, I. Shemyakin, U. B. Singh, A. Somoskovi, R. Skuce, D. van 
Soolingen, E. M. Streicher, P. N. Suffys, E. Tortoli, T. Tracevska, V. Vincent, T. C. 
Victor, R. Warren, S. F. Yap, K. Zaman, F. Portaels, N. Rastogi, and C. Sola. 2006. 
Mycobacterium tuberculosis complex genetic diversity : mining the fourth 
international spoligotyping database (SpolDB4) for classification, population genetics 
and epidemiology. BMC.Microbiol. 6:23. 
 7.  Campos, P. E., P. G. Suarez, J. Sanchez, D. Zavala, J. Arevalo, E. Ticona, C. M. 
Nolan, T. M. Hooton, and K. K. Holmes. 2003. Multidrug-resistant Mycobacterium 
tuberculosis in HIV-infected persons, Peru. Emerg.Infect.Dis. 9:1571-1578. 
 8.  Caoili, J. C., A. Mayorova, D. Sikes, L. Hickman, B. B. Plikaytis, and T. M. 
Shinnick. 2006. Evaluation of the TB-Biochip oligonucleotide microarray system for 
rapid detection of rifampin resistance in Mycobacterium tuberculosis. 
J.Clin.Microbiol. 44:2378-2381. 
Stellenbosch University  http://scholar.sun.ac.za
 27
 9.  CDC. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to 
second-line drugs--worldwide, 2000-2004. MMWR Morb.Mortal.Wkly.Rep. 55:301-
305. 
 10.  Chaves, F., Z. Yang, H. el Hajj, M. Alonso, W. J. Burman, K. D. Eisenach, F. 
Dronda, J. H. Bates, and M. D. Cave. 1996. Usefulness of the secondary probe 
pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J.Clin.Microbiol. 
34:1118-1123. 
 11.  Coggon, G., G. Rose, and D. Barker. 1997. Epidemiology for the uninitated. 
 12.  Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, 
K. Eiglmeier, S. Gas, C. E. Barry, III, F. Tekaia, K. Badcock, D. Basham, D. Brown, 
T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. 
Hamlin, S. Holroyd, T. Hornsby, K. Jagels, B. G. Barrell, and a. et. 1998. 
Deciphering the biology of Mycobacterium tuberculosis from the complete genome 
sequence. Nature 393:537-544. 
 13.  Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, 
and C. Dye. 2003. The Growing Burden of Tuberculosis: Global Trends and 
Interactions With the HIV Epidemic. Arch.Intern.Med. 163:1009-1021. 
 14.  Coronado, V. G., C. M. Beck-Sague, M. D. Hutton, B. J. Davis, P. Nicholas, C. 
Villareal, C. L. Woodley, J. O. Kilburn, J. T. Crawford, T. R. Frieden, and . 1993. 
Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with 
Stellenbosch University  http://scholar.sun.ac.za
 28
human immunodeficiency virus infection in an urban hospital: epidemiologic and 
restriction fragment length polymorphism analysis. J.Infect.Dis. 168:1052-1055. 
 15.  Crofton, J., P. Chaulet, and D. Maher. 1997. Guidelines for the Management of drug 
resistant tuberculosis. 
 16.  Dale, J. W., T. H. Tang, S. Wall, Z. F. Zainuddin, and B. Plikaytis. 1997. 
Conservation of IS6110 sequence in strains of Mycobacterium tuberculosis with 
single and multiple copies. Tuber.Lung Dis. 78:225-227. 
 17.  de Viedma, D. G., N. A. Rodriguez, S. Andres, M. M. Lirola, M. J. Ruiz-Serrano, and 
E. Bouza. 2006. Evaluation of alternatives to RFLP for the analysis of clustered cases 
of tuberculosis. Int.J.Tuberc.Lung Dis. 10:454-459. 
 18.  Denkin, S., D. Volokhov, V. Chizhikov, and Y. Zhang. 2005. Microarray-based pncA 
genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. 
J.Med.Microbiol. 54:1127-1131. 
 19.  Dye, C., S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999. Consensus 
statement. Global burden of tuberculosis: estimated incidence, prevalence, and 
mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 
282:677-686. 
 20.  Edlin, B. R., J. I. Tokars, M. H. Grieco, J. T. Crawford, J. Williams, E. M. Sordillo, 
K. R. Ong, J. O. Kilburn, S. W. Dooley, K. G. Castro, and . 1992. An outbreak of 
multidrug-resistant tuberculosis among hospitalized patients with the acquired 
immunodeficiency syndrome. N.Engl.J.Med. 326:1514-1521. 
Stellenbosch University  http://scholar.sun.ac.za
 29
 21.  Frothingham, R. and W. A. Meeker-O'Connell. 1998. Genetic diversity in the 
Mycobacterium tuberculosis complex based on variable numbers of tandem DNA 
repeats. Microbiology 144 ( Pt 5):1189-1196. 
 22.  Gamboa, F., P. J. Cardona, J. M. Manterola, J. Lonca, L. Matas, E. Padilla, J. R. 
Manzano, and V. Ausina. 1998. Evaluation of a commercial probe assay for detection 
of rifampin resistance in Mycobacterium tuberculosis directly from respiratory and 
nonrespiratory clinical samples. Eur.J.Clin.Microbiol.Infect.Dis. 17:189-192. 
 23.  Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, 
J. Andrews, and G. Friedland. 2006. Extensively Drug Resistant Tuberculosis as a 
cause of death in patients co-infected with Tuberculosis and HIV in a rural area of 
South Africa. Lancet 368:1575-1580. 
 24.  Goguet de la Salmoniere YO, H. M. Li, G. Torrea, A. Bunschoten, J. Van Embden, 
and B. Gicquel. 1997. Evaluation of spoligotyping in a study of the transmission of 
Mycobacterium tuberculosis. J.Clin.Microbiol. 35:2210-2214. 
 25.  Heldal, E., H. Docker, D. A. Caugant, and A. Tverdal. 2000. Pulmonary tuberculosis 
in Norwegian patients. The role of reactivation, re-infection and primary infection 
assessed by previous mass screening data and restriction fragment length 
polymorphism analysis. Int.J.Tuberc.Lung Dis. 4:300-307. 
 26.  Hermans, P. W., D. van Soolingen, E. M. Bik, P. E. de Haas, J. W. Dale, and J. D. 
van Embden. 1991. Insertion element IS987 from Mycobacterium bovis BCG is 
Stellenbosch University  http://scholar.sun.ac.za
 30
located in a hot-spot integration region for insertion elements in Mycobacterium 
tuberculosis complex strains. Infect.Immun. 59:2695-2705. 
 27.  Hewinson, R. G., H. M. Vordermeier, N. H. Smith, and S. V. Gordon. 2006. Recent 
advances in our knowledge of Mycobacterium bovis: a feeling for the organism. 
Vet.Microbiol. 112:127-139. 
 28.  Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2006. Application of the Genotype 
MTBDR assay directly on sputum specimens. Int.J.Tuberc.Lung Dis. 10:1057-1059. 
 29.  Jereb, J. A., R. M. Klevens, T. D. Privett, P. J. Smith, J. T. Crawford, V. L. Sharp, B. 
J. Davis, W. R. Jarvis, and S. W. Dooley. 1995. Tuberculosis in health care workers 
at a hospital with an outbreak of multidrug-resistant Mycobacterium tuberculosis. 
Arch.Intern.Med. 155:854-859. 
 30.  Johnson, R., R. M. Warren, O. J. Strauss, A. Jordaan, A. A. Falmer, N. Beyers, H. S. 
Schaaf, M. Murray, K. Cloete, P. D. van Helden, and T. C. Victor. 2006. An outbreak 
of drug resistant Tuberculosis caused by a Beijing strain in the Western Cape, South 
Africa. Int.J.Tuberc.Lung Dis. 10:1412-1414. 
 31.  Kamerbeek, J., L. Schouls, A. Kolk, M. van Agterveld, D. van Soolingen, S. Kuijper, 
A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. Van Embden. 1997. 
Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for 
diagnosis and epidemiology. J.Clin.Microbiol. 35:907-914. 
Stellenbosch University  http://scholar.sun.ac.za
 31
 32.  Kocagoz, T., Z. Saribas, and A. Alp. 2005. Rapid determination of rifampin 
resistance in clinical isolates of Mycobacterium tuberculosis by real-time PCR. 
J.Clin.Microbiol. 43:6015-6019. 
 33.  Kremer, K., C. Arnold, A. Cataldi, M. C. Gutierrez, W. H. Haas, S. Panaiotov, R. A. 
Skuce, P. Supply, A. G. van der Zanden, and S. D. Van. 2005. Discriminatory power 
and reproducibility of novel DNA typing methods for Mycobacterium tuberculosis 
complex strains. J.Clin.Microbiol. 43:5628-5638. 
 34.  Le Fleche, P., M. Fabre, F. Denoeud, J. L. Koeck, and G. Vergnaud. 2002. High 
resolution, on-line identification of strains from the Mycobacterium tuberculosis 
complex based on tandem repeat typing. BMC.Microbiol. 2:37. 
 35.  Mathema, B., Kurepina, N., Bifani, P., and Kreiswirth, B. Molecular Epidemiology of 
Tuberculosis: Current Insights. Clin.Microbiol.Rev. 19[4], 658-684. 2006.  
Ref Type: Journal (Full) 
 36.  Mazars, E., S. Lesjean, A. L. Banuls, M. Gilbert, V. Vincent, B. Gicquel, M. 
Tibayrenc, C. Locht, and P. Supply. 2001. High-resolution minisatellite-based typing 
as a portable approach to global analysis of Mycobacterium tuberculosis molecular 
epidemiology. Proc.Natl.Acad.Sci.U.S.A 98:1901-1906. 
 37.  Moore, D. A., Evans, C. A., and Gilman, R. H. Microscopic-Observation Drug-
Susceptibility Assay for the diagnosis of TB. New England Journal of Medicine 
355[15], 1539-1550. 12-10-2006.  
Ref Type: Journal (Full) 
Stellenbosch University  http://scholar.sun.ac.za
 32
 38.  Moro, M. L., A. Gori, I. Errante, A. Infuso, F. Franzetti, L. Sodano, and E. Iemoli. 
1998. An outbreak of multidrug-resistant tuberculosis involving HIV-infected 
patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis 
Outbreak Study Group. AIDS 12:1095-1102. 
 39.  Mostowy, S., D. Cousins, J. Brinkman, A. Aranaz, and M. A. Behr. 2002. Genomic 
deletions suggest a phylogeny for the Mycobacterium tuberculosis complex. 
J.Infect.Dis. 186:74-80. 
 40.  Nikolayevskyy, V., K. Gopaul, Y. Balabanova, T. Brown, I. Fedorin, and F. 
Drobniewski. 2006. Differentiation of tuberculosis strains in a population with mainly 
Beijing-family strains. Emerg.Infect.Dis. 12:1406-1413. 
 41.  Pablos-Mendez, A., M. C. Raviglione, A. Laszlo, N. Binkin, H. L. Rieder, F. Bustreo, 
D. L. Cohn, C. S. Lambregts-van Weezenbeek, S. J. Kim, P. Chaulet, and P. Nunn. 
1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. World 
Health Organization-International Union against Tuberculosis and Lung Disease 
Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N.Engl.J.Med. 
338:1641-1649. 
 42.  Sekiguchi, J., T. Miyoshi-Akiyama, E. ugustynowicz-Kopec, Z. Zwolska, F. Kirikae, 
E. Toyota, I. Kobayashi, K. Morita, K. Kudo, S. Kato, T. Kuratsuji, T. Mori, and T. 
Kirikae. 2007. Detection of multidrug resistance in Mycobacterium tuberculosis. 
J.Clin.Microbiol. 45:179-192. 
Stellenbosch University  http://scholar.sun.ac.za
 33
 43.  Somoskovi, A., L. M. Parsons, and M. Salfinger. 2001. The molecular basis of 
resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. 
Respir.Res. 2:164-168. 
 44.  Sreevatsan, S., X. Pan, K. E. Stockbauer, N. D. Connell, B. N. Kreiswirth, T. S. 
Whittam, and J. M. Musser. 1997. Restricted structural gene polymorphism in the 
Mycobacterium tuberculosis complex indicates evolutionarily recent global 
dissemination. Proc.Natl.Acad.Sci.U.S.A 94:9869-9874. 
 45.  Stead, W. W., K. D. Eisenach, M. D. Cave, M. L. Beggs, G. L. Templeton, C. O. 
Thoen, and J. H. Bates. 1995. When did Mycobacterium tuberculosis infection first 
occur in the New World? An important question with public health implications. 
Am.J.Respir.Crit Care Med. 151:1267-1268. 
 46.  Streicher, E. M., R. M. Warren, C. Kewley, J. Simpson, N. Rastogi, C. Sola, G. D. 
van der Spuy, P. D. van Helden, and T. C. Victor. 2004. Genotypic and phenotypic 
characterization of drug-resistant Mycobacterium tuberculosis isolates from rural 
districts of the Western Cape Province of South Africa. J.Clin.Microbiol. 42:891-894. 
 47.  Supply, P., J. Magdalena, S. Himpens, and C. Locht. 1997. Identification of novel 
intergenic repetitive units in a mycobacterial two-component system operon. Mol 
Microbiol 26:99-1003. 
 48.  Supply, P., E. Mazars, S. Lesjean, V. Vincent, B. Gicquel, and C. Locht. 2000. 
Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. 
Mol.Microbiol. 36:762-771. 
Stellenbosch University  http://scholar.sun.ac.za
 34
 49.  Thierry, D., A. Brisson-Noel, V. Vincent-Levy-Frebault, S. Nguyen, J. L. Guesdon, 
and B. Gicquel. 1990. Characterization of a Mycobacterium tuberculosis insertion 
sequence, IS6110, and its application in diagnosis. J.Clin.Microbiol. 28:2668-2673. 
 50.  Traore, H., K. Fissette, I. Bastian, M. Devleeschouwer, and F. Portaels. 2000. 
Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from 
diverse countries by a commercial line probe assay as an initial indicator of multidrug 
resistance. Int.J.Tuberc.Lung Dis. 4:481-484. 
 51.  Traore, H., A. Van Deun, I. C. Shamputa, L. Rigouts, and F. Portaels. 2006. Direct 
detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in 
clinical specimens from tuberculosis patients by line probe assay. J.Clin.Microbiol. 
44:4384-4388. 
 52.  Valway, S. E., S. B. Richards, J. Kovacovich, R. B. Greifinger, J. T. Crawford, and S. 
W. Dooley. 1994. Outbreak of multi-drug-resistant tuberculosis in a New York State 
prison, 1991. Am.J.Epidemiol. 140:113-122. 
 53.  van Embden, J. D., M. D. Cave, J. T. Crawford, J. W. Dale, K. D. Eisenach, B. 
Gicquel, P. Hermans, C. Martin, R. McAdam, and T. M. Shinnick. 1993. Strain 
identification of Mycobacterium tuberculosis by DNA fingerprinting: 
recommendations for a standardized methodology [see comments]. J.Clin.Microbiol. 
31:406-409. 
Stellenbosch University  http://scholar.sun.ac.za
 35
 54.  van Rie, A., R. Warren, M. Richardson, R. P. Gie, D. A. Enarson, N. Beyers, and P. 
D. van Helden. 2000. Classification of drug-resistant tuberculosis in an epidemic 
area. Lancet 356:22-25. 
 55.  van Rie, A., R. M. Warren, N. Beyers, R. P. Gie, C. N. Classen, M. Richardson, S. L. 
Sampson, T. C. Victor, and P. D. van Helden. 1999. Transmission of a multidrug-
resistant Mycobacterium tuberculosis strain resembling "strain W" among 
noninstitutionalized, human immunodeficiency virus-seronegative patients. 
J.Infect.Dis. 180:1608-1615. 
 56.  Victor, T. C., E. M. Streicher, C. Kewley, A. M. Jordaan, G. D. van der Spuy, M. 
Bosman, H. Louw, M. Murray, D. Young, P. D. van Helden, and R. M. Warren. 
2007. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the 
western Cape of South Africa. Int.J.Tuberc.Lung Dis. 11:195-201. 
 57.  Warren, R. M., N. C. Gey Van Pittius, M. Barnard, A. Hesseling, E. Engelke, K. M. 
de, M. C. Gutierrez, G. K. Chege, T. C. Victor, E. G. Hoal, and P. D. van Helden. 
2006. Differentiation of Mycobacterium tuberculosis complex by PCR amplification 
of genomic regions of difference. Int.J.Tuberc.Lung Dis. 10:818-822. 
 58.  Warren, R. M., E. M. Streicher, S. Charalambous, G. Churchyard, G. D. van der 
Spuy, A. D. Grant, P. D. van Helden, and T. C. Victor. 2002. Use of spoligotyping for 
accurate classification of recurrent tuberculosis. J.Clin.Microbiol. 40:3851-3853. 
Stellenbosch University  http://scholar.sun.ac.za
 36
 59.  Watterson, S. A., S. M. Wilson, M. D. Yates, and F. A. Drobniewski. 1998. 
Comparison of three molecular assays for rapid detection of rifampin resistance in 
Mycobacterium tuberculosis. J.Clin.Microbiol. 36:1969-1973. 
 60.  Weyer K. Survey of Tuberculosis drug resistance, 2001-2002, Western Cape. 
http://www.sahealthinfo.org/tb/tbdrugresistance.htm . 2001.  
Ref Type: Electronic Citation 
 61.  WHO. 2004. Anti-TB drug resistance in the world:WHO/ IUATLD global project on 
Anti-Tuberculosis drug resistance surveillance, 1999-2002, Third Report . 
 62.  World Health Organization. 2007. Global Tuberculosis Control: surveillance, 
planning, financing: WHO Report 2007. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 37
Chapter 2 
 
 
Materials and Methods 
 
(Methods will be given in detail in Section 1, whereas buffers and solutions will be 
given in Section 2 of this chapter.) 
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Section 1 
 
Methodology 
 
A. IS6110 RFLP  
 
Extraction of DNA 
 
1. A confluent Lowenstein-Jansen (LJ) slant culture of M. tuberculosis is required for a 
good DNA preparation.   
2. Each LJ slant culture were heat inactivated at 80ºC for 1hour. 
3. Labelled (both on the lid and the tube) 50 ml polypropylene tubes with the 
corresponding isolate number were used.  
4. All work from now onwards was done in a P2 category laminar flow cabinet. This 
was done to protect against contamination of samples and also to protect the person 
doing the extraction against live bacteria.  
5. Once the culture has cooled down (5 to 10 minutes), extraction of DNA can start. To 
each slant, 3ml of Extraction buffer was added to aid in the separation of clumps of 
bacteria and enables easier removal of the colonies from the slants. The buffer 
contains Tris, which is a pH buffer and EDTA, which is a chelating agent. The 
colonies were carefully scraped (without scraping too much media off) off the slant 
with a sterile 10µl loop. The extraction buffer was poured into a labelled sterile 50 ml 
polypropylene tube, which contained approximately 30 X 4mm glass balls (B&M 
Scientific, CGBE0004) to separate colonies during vortex, forming single cell 
suspension. A further 3 ml of extraction buffer was added to the slant. Any remaining 
bacterial colonies were scraped off and the buffer was swirled around in the bottle to 
wash off any bacterial matter on the side of the bottle. This was then also poured into 
the 50 ml tube. The tube was vigorously shaken and vortexed for approximately 2 
minutes.  
6. Proteinase K (10mg/ml) (Roche Molecular Biochemicals, 3115801), RNAse A 
(10mg/ml) (Roche Molecular Biochemicals, 109169) [pre-heat RNAse A at 100oC for 
10 minutes to remove DNAse activity] was put on ice to thaw.  
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7. Lysozyme (50mg/ml) (Roche Molecular Biochemicals, 837059) was left at room 
temperature to thaw.  
8.  Lysozyme with a volume of 500µl and 2.5µl of RNAse A were added to each tube.  
9. Each tube was gently inverted to mix and then incubated at 37ºC for 2 hours.  
10.  After incubation, 600µl of 10x Proteinase K buffer and 150µl Proteinase K was 
added. Each sample was gently mixed and incubated overnight at 45ºC.  
11. The following steps were done in a standard fume hood.  
12. Phenol/Chloroform (Phenol equilibrated, Sigma Aldrich, P4557/ Chloroform, 
MERCK, UN1888) was used to extract DNA. A volume of 5ml of 
Phenol/Chloroform/Isoamyl-alcohol (25/24/1) was added to each bacterial 
preparation and the mixture was gently shaken intermittently for 30 minutes for a 
period of at least one hour. The Phenol/Chloroform/Isoamylalcohol was prepared by 
mixing 480ml chloroform with 20ml of isoamyl-alcohol, after which 400ml of this 
mixture was added to 400ml of phenol. Each sample was centrifuged at 3000rpm for 
20 minutes. The supernatant was carefully aspirated using a P5000 (without any 
interface) pipette and added to a new "labelled" 50ml tube containing 5ml 
chloroform/isoamyl-alcohol. Each tube was gently mixed and centrifuged at 3000rpm 
for 20 minutes. The supernatant was again carefully aspirated and added to a new 
"labelled" 50 ml tube containing 600µl 3M Sodium-Acetate pH 5.5. 
13.  DNA was precipitated by adding 7ml ice-cold (-20ºC) Iso-propanol (Merck, 
5075040LC). Each tube was gently inverted displaying precipitated DNA. With a 
"labelled" pasteur pipette, of which the front end has been melted closed, DNA was 
removed from 50ml tube. The glass pipette with DNA was placed into a 1.5ml 
eppendorf tube containing 1ml of 70% ethanol (absolute ethanol, Merck, 
1.00983.2500) for approximately 1 minute to remove any salt. The glass pipette with 
DNA sticking to it was transferred to a new "labelled" 1.5ml eppendorf tube. DNA 
was left at room temperature until dry. Once dry, an aliquot (300 to 600 µl) of TE was 
added and the pellet was allowed to re-hydrate, after which it was gently shaken off 
the glass rod. DNA was allowed to dissolve by incubation at 60ºC or at 4ºC 
overnight. 
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Extremely important: If the amount of DNA, after the precipitation step, was 
insufficient, the 50ml tube was placed in the freezer at -20ºC overnight. This was 
followed by centrifugation at 3000rmp for 20 minutes at 4ºC. The supernatant was 
carefully poured out (taking care not to pour the sediment out). To remove the salts 
10ml of ice cold 70% ethanol was added. The sample was centrifuged under the same 
conditions as above for 10 minutes. The ethanol was poured out and tube was 
inverted on a blotting paper or paper towel. The tube was placed in 65ºC oven for 
about 10 minutes or at 37ºC until dry. The pellet was re-hydrated and dissolved with 
TE pH 8.0 (300 to 600μl).  
 
14. If DNA does not dissolve after extended incubation then it was re-purified as follows: 
For re-purification of DNA, 0.1 x volume Protenase K buffer and 1/40 x volume 
Protenase K were added to the mixture and gently mixed. DNA was incubated at 45 
ºC overnight. Phenol/chloroform extraction was done, by adding half volume of 
Phenol/Chloroform to the bacterial preparation and the mixture was shaken well and 
often for about 20 minutes. Half the volume of chloroform/isoamyl-alcohol was 
aliquoted into a sterile 1.5ml eppendorf tube and 1/60 x volume 3M Sodium-Acetate 
(to adjust the pH) into another tube. The sample was centrifuged at 3000rpm for 20 
minutes. The aqueous phase was carefully aspirated off, using a P1000 pipette (if the 
aqueous phase was very viscous, the front of the pipette tip was cut off), ensuring that 
none of the inter-phase or phenol-phase was taken. The aqueous phase was added to 
the chloroform/isoamyl-alcohol and the tube was marked. After thorough mixing, the 
sample was centrifuged again at 3000rpm for 20 minutes. The aqueous phase was 
collected and added to the Na-acetate.  
15. The DNA was stored at –20 ºC.  
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Determining the concentration of DNA 
 
1. DNA was measured using the Nanodrop (ND-1000 Spectrophotometer, Inqaba 
biotec, S.A) according to the manufacturer’s instructions. These measurements 
were then used to calculate DNA concentrations. 
2. At least 2µl DNA of each sample was used (the optical density (OD) of 1 OD at 
260nm is equivalent to 50μg/μl of double-stranded DNA). 
 
Restriction Enzyme Digestion of the DNA 
 
1. Usually 6 µg of M. tuberculosis DNA is used per digest with the restriction 
enzymes PvuII (Laboratory Specialist Services, R0151-L). The reason for the 6μg is 
to do 2 reactions of 3μg each. Each eppendorf tube was clearly marked with the 
sample number and the restriction enzyme used.  
2. The prescribed buffer for the enzyme was allowed to thaw.  
3. DNA was allowed to thaw and dissolved uniformly by incubating at 65ºC for 30 
minutes and followed by gentle mixing. 
4. The digestion was done in a total volume of 100µl and the order of addition was as 
follows: 10 µl of 10x Restriction Buffer  
  µl H2O (accordingtocalculation) 
  µl DNA (according to calculation) 
     Vortex 
     2.5 µl Restriction Enzyme (if the activity is 12u per µl, otherwise adapt to 
use 5u per g of DNA). The normal standard: 1U/μg = 1μg/μl DNA for plasmid 
DNA and 5μg/μl DNA for chromosomal DNA. The total volume of the digest 
mixture should be 100μl.  
     Vortex 
(The digestion components should be added in this order otherwise the digestion 
process would not be optimal. When the restriction enzyme is added before the 
DNA, it will denature because the conditions for the functioning of the enzyme are 
not optimal.) 
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5. The digestion mix was mixed just before and just after the addition of the enzyme. 
(Mixing of the components are important so that the components can be distributed 
evenly throughout the tube otherwise the digestion will not be optimal.) The 
digestion mixture was incubated overnight at 37ºC (minimum 3 hours).  
6. After digestion, the reaction was incubated at 65ºC for 10 minutes to inactivate any 
remaining enzyme activity. (Inactivating the enzyme with heat won’t interfere with 
MgCl2 concentration. Since EDTA is a chelating agent, it will bind to the divalent 
cation (Mg2+) and remove it. The Mg2+ is important for enzyme function if 
digestion was to be repeated.) 
 
Gel Electrophoresis of Restricted DNA (Test gel) 
 
1. To test whether DNA was digested, 4µl of 6x Loading Buffer and 8µl of the 
digested sample was mixed in a 0.5ml eppendorf tube. The mixture was loaded 
(8µl) onto a 1% agarose gel (Whitehead Scientific, D1-LE) dissolved in TBE. No 
marker was loaded, because only the amount of digested DNA were judged, not the 
size of the bands. The amount was judged according to the presence of a smear, 
which is evenly spread, and if digestion did not occur there will not be a smear. The 
test gel for PvuII is run overnight at 40 Volts and 19 Amps. The voltage is increased 
if the gel is run for 3- 4 hours (100-110 volts). The gel chamber is 20cm wide by 25 
cm long. 
2. The gel was stained with 50µl ethidium bromide (interchelating agent) in 500ml of 
TBE running buffer with constant shaking for 30 minutes. 
3. DNA was visualized by UV light (245 nm). (The gel picture was used to calculate 
the volume in which each sample DNA should be re-dissolved in before the 
fingerprinting gel is prepared.) 
 
Stellenbosch University  http://scholar.sun.ac.za
 43
Gel Electrophoresis of Restricted DNA (fingerprinting gel) 
 
1. If DNA was digested, it was precipitated by adding 10µl 3M Sodium Acetate (pH 
5.2) and 330µl of 100% Ethanol.  
2. It was mixed well by vortexing and incubated at –20ºC overnight.  
3. To pellet DNA, each sample was centrifuged at 10000xg for 30 minutes at 4 ºC.  
4. The supernatant was carefully aspirated off without disturbing the pellet. 
Approximately 50ul was left behind in the tube. To each tube, 500µl 70% ethanol 
was added to wash the sodium acetate salt out of the DNA pellet. 
5. Centrifugation of DNA was repeated at 10000xg for 30 minutes at 4 ºC.  
6. DNA pellet was left to dry at room temperature and in moist instances, overnight. 
7. Dried DNA pellets were re-dissolved in a specific volume of bromophenol blue 
buffer (standard 6x application buffer containing marker X) according to the 
ethidium bromide intensity of the test gel. The volume of the buffer added to each 
sample should be chosen relative to a chosen reference band intensity and volume. 
Samples with higher intensity bands will need a relatively higher volume of the 
buffer than the reference band and the lower intensity bands will require relatively 
lower volume of the buffer than the reference bands. (The volume of the reference 
band should be standard for each laboratory in all the analysis done. In our case 
20µl was used as the reference volume and the volume added to each sample 
adjusted according to the band intensity as described above). The buffer was made 
as follows; 4ml of 6X loading buffer, 12ml Tris -EDTA buffer, 13.2µl Marker X 
(250ng/µl), which was aliquoted into 1.5ml eppendorf tubes and stored at -20ºC. 
DNA was allowed to dissolve in the buffer by incubation at 65ºC.  
8. DNA (10 µl) that was re-dissolved was electrophoretically fractionated in a 0.8% 
agarose gel with TBE pH8.3 at 65 Volts overnight (until the bromophenol blue has 
migrated approximately 23 cm). 
9. The fractionated DNA in the agarose gel was stained by incubating the agarose gel 
in 500ml TBE containing 50µl (10mg/ml ethidium bromide) for 30 minutes.  
10. The gel was then photographed to determine the resolution of fractionation and the 
loading intensity.  
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Southern Transfer of the Fingerprinting gel 
 
1. DNA from a fingerprinting gel was transferred from the agarose onto a charged 
Nylon membrane (HybondN+, AEC Amersham, RPN 203B) by Southern Transfer.  
2. Gloves were worn whenever handling the gel and nylon membrane.   
3. After the gel was photographed, it was inverted into a plastic dish, using the gel 
tray. DNA was denatured in the gel by covering with denaturing buffer and gently 
shaken for 20 – 25 minutes. The denaturing solution was then sucked off the gel 
with a Venturi pump and the gel was covered with neutralizing buffer. The gel was 
again gently shaken for 20 – 25 minutes. 
4. The membrane was labelled with a black ballpoint pen to allow future recognition.  
5. Orientation marks were spotted onto the membrane to allow future alignment of 
resultant autoradiographs. Aliquots of 0,2µl were spotted in six positions on the 
membrane on the same side onto which the DNA had to be transferred. 
6. The membrane was hydrated in H2O and then transferred to a dish with 20x SSPE 
solution. The transfer of DNA was as described in “Molecular Cloning” (Sambrook, 
Fritsch, Maniatis).   
7. The gel was carefully placed, face down onto a blotting tray covered with Whatman 
(3MM[Merck, 3030917]) blotting paper. The wells of the gel were removed by 
cutting with a surgical blade and trimmed at the bottom (if necessary). Air bubbles 
were removed under the gel by rolling over the gel with a 10ml pipette. The 
correctly pre-treated (see above) labelled membrane was placed (spotted side on the 
side containing the labelling, i.e. downwards) on top of its corresponding gel and air 
bubbles were removed if any were present.  
8. The exposed portions or sides of the wet blot block (gel + membrane) were covered 
with strips of parafilm to ensure that the fluid flows through the gel rather than 
short-circuiting the gel. 
9. Whatman blotting papers were cut to the size of the blot block and individually 
hydrated first in H2O and then in 20 × SSPE. The papers (x2) were placed on the 
blot blocks. All air bubbles, if any, were removed.  
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10. One pack of paper towels (2 inches high) was placed on top of the Whatman papers 
(i.e. one blot block = one pack paper towels).  
11. A plastic gel tray with a 1000ml weight was placed on top of the towels. The 
blotting tray was filled with 20 × SSPE to within ½ inch from the top of the wet 
blot blocks. 
12.  The transfer was done overnight.  
13. After transfer, the membrane was removed and baked at 80ºC for 2 hours (between 
2 sheets of Whatman blotting paper). After baking, the membrane was sealed in a 
plastic sleeve and stored at 4ºC until further use.  
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ECL labelling and hybridisation 
It was done according to the manufactures instructions 
 
1.  Pre-hybridisation and hybridisation was done in a flat-bottomed plastic dish in a 
shaking water-bath (rpm). The hybridisation sleeve was kept in place by a sealed 
plastic bag, containing 500ml water, which also aid in the even distribution of the 
buffer over the membrane.  
2. The membrane was sealed in a plastic bag with 40ml gold buffer, which acts as a 
blocking agent since it contains the blocking agent gelatin and NaCl, which 
determines the stringency of hybridisation. It is crucial that all air bubbles were 
removed. Pre-hybridised was done at 42ºC for a minimum of 1 hour. 
3. The ECL labelling and detection kit (AEC Amersham, RPN3001) was used. The 
probe (3’ or X [DNA Molecular Weight Marker X, Roche Molecular 
Biochemicals, 1498037001]) was made up to 15µl in a 0.5ml eppendorf tube.  
 
PCR reaction for constructing 3’ probe 
 
• The probe was amplified by PCR from the plasmid-DNA.  
• Reaction mixture contained the following:  
195,5 µl of dH2O 
100 µl Q buffer 
50 µl 10X buffer 
40 µl MgCl2  
80 µl dNTP 
10 µl Forward primer - 5’-TCG GTC TTG TAT AGG CCG TTG-3’ : 50pmol/mL.   
10 µl Reverse primer - 5’-ATG GCG AAC TCA AGG AGC AC-3’ : 50 pmol/mL.   
2,5 µl Taq polymerase 
2 µl plasmid DNA pIS986  
 
• This was mixed and amplified by PCR using the following cycle: 
Denaturation :95ºC for 15 minutes 
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Annealing     :94ºC for 1 minute, 62ºC for 1minutesute, 72ºC for 1 minute 
Elongation    :72ºC for 10 minutes 
Amplification was confirmed by fractionation on 2% agarose gel after staining 
with ethidium bromide. 
 
The amplified fragment was purified using the SV kit from Promega 
(Whitehead Scientific, #A9281). An equal volume of membrane binding buffer 
was added to the PCR reaction and mixed well. Solution was transferred to 
membrane and allowed to bind for 1 minute followed by gentle removal of 
solution through the membrane. The membrane was washed twice with 700ul 
wash buffer followed with 500ul wash buffer. The membrane cup was 
centrifuged for 5 minutes at 13000 rpm to remove excess wash buffer. 
Amplified DNA was eluted by adding 50ul H2O (preheated to 65ºC). Amplicon 
concentration was determined as described above and stored at -20ºC. 
 
4. Water (13µl) was added to 200ng DNA (did not use TE since labelling will not 
take place as N in Tris will compete with N-groups on DNA for cross-linking of 
the Horse Radish Peroxidase). 
5. The probe was denatured at 100ºC for 5 minutes and immediately put on ice for a 
further 5 minutes.  
6. Of the Labelling Mix (Horse Radish Peroxidase), 15µl of was added and mixed.  
7. Of the Glutaraldehyde solution, 15µl of was added, mixed and incubated at 37ºC 
for 10 minutes.  
8. The hybridisation bag was taken from the water-bath and cut open at one end. An 
automatic pipette was used to put the probe into the bag and the bag was sealed 
immediately. A pipette was rolled over the membrane in the bag to mix the 
labelled probe and the hybridisation buffer. The bag was sealed after excluding all 
air bubbles and put back in the plastic dish under the weight and incubated 
overnight at 42ºC in the shaking water-bath (72 rpm).  
9. After hybridisation, the membrane was removed from the hybridisation bag for 
the washing steps. The membrane was washed twice at 42oC for 20 minutes each 
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in a plastic dish with 400ml primary buffer. The second wash was recycled as the 
first wash of another membrane.  
10. This was followed by 2 washes, 5 minutes each, at room temperature in 400ml 2 
× SSC.  
11. The membrane was then placed in a new plastic sleeve and all excess liquid 
removed. 
12. Instead of 4ml as mentioned in the original protocol, 3ml of the two detection 
reagents were mixed in a McCartney tube and mixed.  
13.  These reagents were poured onto the membrane in the plastic sleeve. The 
solution was gently spread, by rolling with a pipette over the membrane for a 
period of 90 seconds and then pushed out of the bag.  
14. The bag was sealed and exposed to X-ray film for an optimum period of time 
(varying between 1 minute to 2 hours). The film was initially exposed for a 
shorter period to assess the strength of the signal. 
15. If membranes were needed to be repeated, stripping of the membranes consisted 
of a single wash with 100ºC 0.1% SDS until cool. 
 
 
Analysis of IS6110 genotypes 
 
IS6110 genotypes were analysed using Gelcompar II (Version 4.0, Applied Maths, BVBA, 
Kortrijk, Belgium). The unweighted pair group method with arithmetic mean (UPGMA), 
based on the Dice coefficient was used for cluster analysis with band-matching tolerance 
parameters allowing for a 5% shift in each pattern as a whole and a 0.5% variance in 
individual band positions. Strain families were classified according to a similarity index of 
65%. Isolates were grouped into clusters (strains with identical IS6110 genotype) and 
uniques (strains demonstrating IS6110 genotype patterns that are not identical to any other 
IS6110 genotype pattern). For quality control of DNA band assignment, additional analysis 
by colleagues was done. 
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B. Spoligotyping 
 
Table 1: Spoligotyping Polymerase Chain Reaction mix  
PCR MIX 50µl 
H2O 23µl 
10× buffer 5µl 
MgCl2 5µl 
dNTPs (0.4 mM) 4µl 
Dra (Isogen)* 4µl 
DRb (Isogen)* 4µl 
Tag polymerase (Promega) 0.5µl 
 
*Isogen LIFE SCIENCE, Lagedijk Noord 18, 3401 VA IJsselstein. 
 
PCR Cycles 
95°C  for 3 minutes 
94°C  for 1 minute 
55°C  for 1 minute 
72°C  for 30 seconds 
72°C  for 10 minutes 
 
Cycles of ×30 but can vary from 28-35 cycles 
 
1 After PCR amplification, 20µl PCR products were added to 150µl 2xSSPE/0.1%SDS. 
2 The diluted PCR products were heat-denatured for 10 minutes at 99ºC and cooled on 
ice immediately. 
3 The membranes (Isogen LIFE SCIENCE, Lagedijk Noord 18, 3401 VA IJsselstein) 
were washed at 57ºC in 2xSSPE/0.1%SDS for 5 minutes. 
4 The membranes were placed on a support cushion in a miniblotter (Immunetics, 
Cambridge, MA 02139) with slots perpendicular to the line pattern. 
5 The residual fluid was removed from the slots by aspiration. 
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6 The slots were carefully filled with diluted denatured PCR products to avoid air 
bubbles. 
7 Hybridisation occurred on a horizontal surface for 60 minutes at 57ºC. 
8 The samples were removed from the blotter by aspiration. 
9 The membranes were washed twice in 2xSSPE/0.5%SDS for 5-10 minutes at 57ºC. 
10 Exactly 40ml 2xSSPE/0.5%SDS (42 ºC) was added to 10µl Strepavidine-peroxidase 
conjugate (500U/ml) (Isogen LIFE SCIENCE, Lagedijk Noord 18, 3401 VA 
IJsselstein), which was incubated at 42ºC for 45-60 minutes. 
11 The membranes were washed twice with 2xSSPE/0.5%SDS at 42ºC for 5-10 minutes. 
12 This was followed by two washes with 2xSSPE for 5 minutes at room temperature. 
13 The membranes were then incubated in 20ml (10ml solution 1 + 10ml solution 2) ECL 
mix for 1.5 minutes. 
14 Visualization of spacer sequences follows after exposure to film for 5-20 minutes. 
15 For repeated use of membranes, the membranes were washed twice in 1% SDS at 80 
ºC for 30 minutes to 1 hour 
16 The membranes were then stored at 4 ºC in 20mM EDTA pH8 (overnight). 
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C. MIRU-VNTR 
 
Reaction mixture for Polymerase Chain Reaction amplification: 
For the reaction to take place, 0.2μg template DNA was used. Of  boiled cultures, 1μl DNA 
was used and if DNA was purified, 1μl of a 1 in 40 dilution was used. The following 
reagents were used in the reaction:  
5 μl Q-Buffer, 2.5μl 10 x Buffer, 2μl 25 mM MgCl2, 4μl 10 mM dNTP’s, 1μl of each 
primer (50 pmol/μl) (for VNTR: dilute primers to 1 in 16), 0.125 μl HotStarTaq DNA 
polymerase (Qiagen, Germany) made up to 25 μl with H2O. 
 
In a separate demarcated room (no bacterial DNA was allowed in this room), all of the 
above reagents were added except for the DNA, into an eppendorf tube.  
 
Reagents were added in the following order: 
1. H2O 
2. Q-Buffer 
3. 10 x Buffer 
4. MgCl2 
5. dNTP’s 
6. primer (see below) 
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Primers for MIRU loci 
 
Alleles loci Primer sequence (5’-3’) 
MIRU 2F 
MIRU 2R 
154 
TGG ACT TGC AGC AAT GGA CCA ACT 
TAC TCG GAC GCC GGC TCA AAA T 
MIRU 4F 
MIRU 4R 
580 
GTC AAA CAG GTC ACA ACG AGA GGA A 
CCT CCA CAA TCA ACA CAC TGG TCA T 
MIRU 10F 
MIRU 10R 
960 
GTT CTT GAC CAA CTG CAG TCG TCC 
GCC ACC TTG GTG ATC AGC TAC CT 
MIRU 16F 
MIRU 16R 
1644 
TCG GTG ATC GGG TCC AGT CCA AGT A 
CCC GTC GTG CAG CCC TGG TAC 
MIRU 20F 
MIRU 20R 
2059 
TCG GAG AGA TGC CCT TCG AGT TAG 
GGA GAC CGC GAC CAG GTA CTT GTA 
MIRU 23F 
MIRU 23R 
2531 
CTG TCG ATG GCC GCA ACA AAA CG 
AGC TCA ACG GGT TCG CCC TTT TGT C 
MIRU 24F 
MIRU 24R 
2687 
CGA CCA AGA TGT GCA GGA ATA CAT 
GGG CGA GTT GAG CTC ACA GAA 
MIRU 26F 
MIRU 26R 
2996 
TAG GTC TAC CGT CGA AAT CTG TGA C 
CAT AGG CGA CCA GGC GAA TAG 
MIRU 27F 
MIRU 27R 
3007 
TCG AAA GCC TCT GCG TGC CAG TAA 
GCG ATG TGA GCG TGC CAC TCA A 
MIRU 31F 
MIRU 31R 
3192 
ACT GAT TGG CTT CAT ACG GCT TTA 
GTG CCG ACG TGG TCT TGA T 
MIRU 39F 
MIRU 39R 
3192 
CGC ATC GAC AAA CTG GAG CCA AAC 
CGG AAA CGT CTA CGC CCC ACA CAT 
MIRU 40F 
MIRU 40R 
802 
GGG TTG CTG GAT GAC AAC GTG T 
GGG TGA TCT CGG CGA AAT CAG ATA 
 
 
The mixture was vortexed followed by the addition of: 
 
7. HotStarTaq DNA polymerase 
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The mixture was vortexed again followed by addition of DNA in another room (should be 
free of PCR amplicons). After DNA has been added to the reaction mixture, samples were 
placed in vortex, ready for amplification. 
 
Amplification: 
 
1. incubation at 95°C for 15 minutes 
2. 35 - 45 cycles at 94°C for 1 minute 
3. annealing temperature for 1 minute, 
4. 72°C for 1 minute 
5. After the last cycle, the samples were incubated at 72°C for 10 minutes. 
 
Primers and polymerase chain reaction conditions for VNTR’s  
 
MIRU loci 
Primer dilutions 
(normal primer stock = 
(50 pmol/μl) 
12-
loci 
set 
TM Cycles 
Miru 2 1/16 ? 62 35 
Miru 4 1/16 ? 62 35 
Miru 10 1/16 ? 62 35 
Miru 16 1/16 ? 62 35 
Miru 20 1/16 ? 62 35 
Miru 23 1/16 ? 62 35 
Miru 24 1/16 ? 62 35 
Miru 26 1/16 ? 62 35 
Miru 27 1/16 ? 62 35 
Miru 31 1/16 ? 62 35 
Miru 39 1/16 ? 62 35 
Miru 40 1/16 ? 62 35 
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After amplification, the PCR amplification products were electrophoretically fractionated 
in 3.0% agarose in 1xTBE pH 8.3 at 6V/cm for 4 hours. To each sample, 5ul of loading dye 
was added, mixed and 8µl of each mixture was added in a slot on the gel. After 4 hours, 
DNA were visualized by staining with ethidium bromide. The existence of an event was 
determined by the presence or absence and the size of the respective PCR product. 
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D. PCR Amplification of Drug Resistant Genes 
A PCR amplification based method was used for the detection of mutations followed by 
sequencing of amplified products with an ABI PRISM (model 377, Perkin Elmer, Foster 
City, CA, USA). Table 2 describes the primers designed for the mutations associated with 
resistance to various drugs. Mutations were screened in katG (INH), inhA promoter (INH), 
rpoB (RIF), pncA (PZA), emb (Emb)  and gyrA (Ofx) genes. 
 
Table 2: Primer sequences targeting specific genes 
Gene 
Primer 
name 
Primer sequence Size Tm Reference 
katG 
RTB 59 
RTB 38 
TGGCCGCGGCGGTCGACATT 
GGTCAGTGGCCAGCATCGTC 
419 62 Victor et al 1999(3) 
inhA 
inhA P5 
InhA P3 
CGCAGCCAGGGCCTCGCTG 
CTCCGGTAACCAGGACTGA 
246 55 Victor et al 1999(3) 
rpoB 
rpoB For 
rpoB Rev 
TGGTCCGCTTGCACGAGGGTCAGA 
CTCAGGGGTTTCGATCGGGCACAT 
437 
78 
76 
Victor et al 1999(3) 
pncA 
pncA F 
pncA R 
AGTCGCCCGAACGTATGGTG 
CAACAGTTCATCCCGGTTCG 
615 62 Louw et al 2006(2) 
embB 
emb151 
emb131 
CGGCATGCGCCGGCTGATTC 
TCCACAGACTGGCGTCGCTG 
260 64 Johnson et al 2006(1) 
gyrA 
gyrA R 
gyrA F 
CTGGCGAGCCGAAGTTG 
GAGACCATGGGCAACTACCA 
124 62 Current 
 
Amplified PCR products were run on 1% gel in 1× TBE buffer at 100 V for 2 hours. 
PCR products cleaned using ExoSAP-IT (AEC Amersham, 78201) followed by 
sequencing. 
 
E. Phylogenetic Analysis 
The non-synonymous single nucleotide polymorphisms (nsSNPs) were used to construct a 
phylogenetic tree. Analysis was done using the neighbour joining algorithm (PAUP 4.0*; 
Phylogenetic Analysis Using Parsimony (*Other Methods) Version 4b10. Sinauer 
Associates, Sunderland, Massachusetts) with bootstrapping to determine the statistical 
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support for nodes within each phylogenetic reconstruction. The program, contree (PAUP 
4.0*) was used to generate a consensus tree combined with the majority rule formula. 
 
Section 2 
 
Buffers and solutions 
 
A. IS6110 RFLP 
 
Extraction buffer    50g Mono Sodium Glutamic Acid (MSG) 
(1 litre)     6.06g Tris 
      9.3g EDTA 
      pH 7.4 with HCl 
 
10× Proteinase K buffer   6.05g Tris 
(500ml)     9.3g EDTA 
      25g SDS 
 
3M Sodium Acetate (3M Na-Ac)  40.82g Na-Ac-3H2O 
(100ml)     pH 5.5 with Glacial Acetic Acid 
 
70% ethanol     700ml of absolute ethanol 
      300ml distilled H2O  
 
TE      1.211g Tris 
(1 litre)     0.372g EDTA 
      pH 8.0 
 
Application buffer    30 ml 100% Glycerol 
(100ml)     Bromo-Phenol Blue 
      0.6g SDS 
      TE to make up to 100ml 
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10× TBE     216g Tris 
(2 litre)     110g Boric Acid 
      14.88g EDTA 
1% Test Gel    3g DLE agar 
      300ml 1× TBE 
 
Blue Running Buffer with Marker X 6.6μl Marker X (Boeringer Mannheim) 
      (To give total of 2ng per well) 
      8 ml of 1:3 dilution of Running buffer 
0.8% Proper Gel    2.4g SEAKEM agar 
      300ml 1× TBE 
 
Orientation Marker “Spotter”  2μl of 0.25μg/μl Marker X  
      20μl of 1.25 µg/µl MTB DNA (H37Rv) 
      (Total of 2.5μg DNA) 
      23μl TE 
      Total of 45μl 
      Add 45μl 0.8M NaOH 
 
Denaturing buffer    87.66g NaCl 
(1 litre)     20g NaOH 
 
Neutralization buffer   87.66g NaCl 
(1 litre)     60.5g Tris 
 
20× SSPE     175.3g NaCl 
(1 litre)     27.6g NaH2PO4.H2O 
      7.4g EDTA 
      pH 7.4 with NaOH pellets (approx. 8g) 
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Nucleic Acid Transfer Buffer (20× SSC) 350.6g NaCl 
(2 litre)     176.4g Tri-Sodium Citrate (hydrous)/ 
      Tri-Na Citrate (anhydrous) 
      PH 7.0 
Primary Wash for ECL Blots  720g Urea 
(2 litres)     8g SDS 
      25ml 20× SSC 
 
Stripping buffer (0.1% SDS)  20ml 10% SDS 
      Distilled H2O up to 2 litres 
 
B. Spoligotyping 
 
10× SSPE 13.7g Sodiumhydrogen Phosphate 100mM 
(1 litre)     105.19g Sodium Chloride -18M 
      3.36g EDTA – 10mM 
      pH 7.4 
 
10% SDS  50g SDS 
(500ml)      
 
0.5 M EDTA    93g EDTA 
(500ml) 
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Working stock solutions 
500ml 2×SSPE/0.1% SDS  100ml 10× SSPE 
      5ml 10% SDS 
1 litre 2×SSPE/0.5% SDS 200ml 10×SSPE 
      50ml 10% SDS 
1 litre 1% SDS    100ml 10% SDS 
500ml 20mM EDTA   20ml 0.5M EDTA 
      
C. MIRU-VNTR 
 
3% PCR Gel 3g agarose 
 300ml 1× TBE pH 8.3 
 
D. PCR Amplification of Drug Resistant Genes 
 
PCR gel 1.25g DLE agarose 
 100ml 1× TBE pH 8.3 
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Summary 
 
Background: Despite an excellent tuberculosis (TB) control program, extensively drug 
resistant TB (XDR-TB) has emerged in a gold mine located in the North West province of 
South Africa.  We investigated the mechanisms leading to the development of MDR and 
XDR-TB in this setting.  
 
Methods: TB control was in strict accordance to the WHO DOTS and DOTS-Plus 
guidelines and TB was proactively diagnosed by chest x-ray, smear and culture in this 
setting.  The study cohort consists of TB cases infected with drug-resistant Mycobacterium 
tuberculosis strains.  Demographic data were obtained from all cases and cultures were 
subjected to drug-susceptibility testing and genotyping by standard procedures. 
 
Findings: Between 2003-2005, 128 cases were diagnosed with drug-resistant TB, of which 
10% were isoniazid mono-resistant, 5% were multiple drug resistant and 85% were multi 
drug resistant TB (MDR-TB). Of the MDR-TB isolates, 5% were XDR-TB.  The drug-
resistant epidemic resulted from importation, acquisition and transmission.  MDR-TB was 
primarily transmitted, however, risk factors for transmission were over-whelmed by the 
incidence of HIV co-infection.  Contrary to previous findings, a large proportion of HIV 
co-infected cases were smear positive, perpetuating the epidemic.  Phylogenetic analysis of 
the largest cluster showed how drug-resistance was sequentially acquired possibly as a 
direct consequence of treatment guidelines.  
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Interpretation: TB control measures over and above those recommended by the WHO are 
necessary to control the spread of drug-resistant TB in a setting with a high incidence of 
HIV.  In the study setting, efforts made by the TB control programme were compromised 
by an influx of disease, emphasising the need to ensure well functioning TB control 
programs in all settings.  Failure to rapidly diagnose drug-resistant TB lead to transmission 
thereby highlighting the need to address clinical as well as laboratory diagnostic delay 
more vigorously.  The absence of rapid diagnostics promoted the acquisition of additional 
resistance through inappropriate treatment regimes, culminating in the evolution of XDR-
TB.   
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3.1. Introduction  
 
Failure to implement proper tuberculosis (TB) control programs and correctly manage TB 
cases has been ascribed as the primary reason for the emergence of drug resistant TB (1).  
Drug resistance evolves through the sequential acquisition of mutations in specific genes of 
the bacterium, Mycobacterium tuberculosis (M. tuberculosis), and the subsequent selection 
of sub-populations carrying mutations conferring drug resistance (2).  Resistance to the two 
first-line anti-TB drugs, isoniazid (INH) and rifampicin (RIF) with or without resistance to 
other first-line drugs has been termed Multi Drug Resistant TB (MDR-TB) and is of 
particular concern to TB control due to the cost and duration of treatment.  Globally, an 
estimate of 424,203 MDR-TB cases are diagnosed each year (3), while in South Africa it is 
estimated that more than 6000 new MDR-TB cases are diagnosed each year (4).  Together, 
this demonstrates the inability of TB control strategies and programmes to ensure 
adherence and completion of TB treatment regimens to restrict the development and spread 
of this difficult-to-treat form of TB disease.  
 
More recently, concern at a global level has been raised over the emergence of Extensively 
Drug Resistant TB (XDR-TB) (5).  XDR-TB has been defined as MDR-TB with additional 
resistance to a Fluoroquinolone and one or more of the injectable drugs Kanamycin (K), 
Amikacin (A), and Capreomycin (C) (6).  A joint global survey by the World Health 
Organization (WHO) and the Centres for Disease Control (CDC) identified XDR-TB in all 
regions of the world, thereby recognising this as a new threat to TB control (7).  In South 
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Africa, an XDR-TB outbreak involving fifty-three cases (8), raised concern because of the 
high mortality of this disease among HIV co-infected patients. 
 
Drug resistance surveys in South Africa have suggested that acquired resistance was the 
main cause of MDR-TB and thereby implied poor patient compliance (9). In contrast, 
molecular epidemiological studies have demonstrated that MDR-TB may be primarily 
transmitted (10), possibly as a result of diagnostic delay.  In 2003, an increase in the 
number of MDR-TB cases was noted at a mine hospital supplying comprehensive health 
care to a number of mines in the region.  However, despite a Directly Observed Therapy 
Short-course (DOTS) based TB control program that achieves WHO targets for successful 
outcomes for new sputum smear positive TB (averaging 89%), the incidence of TB and 
drug resistant TB continued to increase.  
In this study, we used a molecular epidemiological approach together with clinical and 
epidemiological data to understand how sequential acquisition of resistance could lead to 
the evolution of MDR-TB and XDR-TB within a well-functioning TB control program. 
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3.2. Materials & Methods 
 
This study was approved by the ethics committee (IRB) of Stellenbosch University, 
Tygerberg, South Africa (Ref. 2002/C118). 
 
3.2.1. Study Setting and Population 
 
This study was done in a gold mine (between the period of December 2002 to November 
2005) in the North West province, South Africa.  The TB control program in this setting 
has been modelled on the WHO recommendations for TB programs, the South African 
National TB Control Program and the Guidelines for TB Control in the Mining Industry of 
the Department of Mineral and Energy Affairs of South Africa.  All employees are 
subjected to a 6 monthly chest x-ray for occupational lung disease screening.  The 
bacteriological diagnosis of Pulmonary TB (PTB) was made by Auramine-O fluorescent 
stain microscopy of 4 sputum smears and 2 TB cultures using Mycobacterial Growth 
Indicator Tube (MGIT) (Bectin Dickenson, USA).  Drug susceptibility testing (DST) for 
INH and RIF was done, using the MGIT technique, on all cultures that provided a positive 
growth and were identified as M. tuberculosis, using the Gen/Probe kit at the in-hospital 
laboratory.  DST for streptomycin (S) and ethambutol (Emb) were routinely performed on 
all isolates resistant to INH or RIF.  INH and RIF resistant cultures (MDR-TB) were sent to 
the National Health Laboratory Service (NHLS) for second-line DST using Middlebrook 
7H10 agar containing critical concentrations of 20 µg/mL ethionamide (Eto), 2 µg/mL 
ofloxacin (Ofx) and 5 µg/mL kanamycin (K).  Pyrazinamide (PZA) DST was done 
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according to the BACTEC manual (BD Diagnostic Systems, Franklin Lakes, NJ, USA) 
(11).  
All bacteriologically confirmed TB cases were treated using DOTS.  Confirmed new cases 
were treated using a 6 month course of therapy comprising 2 months HRZE and 4 months 
HR.  Re-treatment cases were treated with an 8 month course of therapy comprising 2 
months HRZES, 1 month HRZE and 5 months HRE according to the WHO/IUATLD 
guidelines.  All cases were initially hospitalised where they received daily supervised 
treatment.  Cases were discharged from hospital when their sputum smears were negative 
or scanty positive and negative (2 successive sputum specimens collected 24 hours apart, 
checked weekly).  Thereafter these cases were treated as outpatients where they received 
supervised treatment, 5 days per week.  
 
Cases identified with MDR-TB were hospitalised and treated according to the DOTS-Plus 
strategy using Guidelines for the treatment of MDR-TB from the South African National 
TB control program.  Drugs utilised for the treatment of MDR-TB cases included, 
Ofloxacin (Ofx), Ethionamide (Eto), Pyrizinamide (Z), either Ethambutol (Emb) or 
Terizidone (Tz), one of the injectable aminoglycosides Streptomycin (S), Kanamycin (K), 
or Amikacin (A), with the addition of Clarythromycin (Clr). The respective drugs were 
used in dosages appropriate to the weight and clinical condition of the individual patient 
with higher dose Clr being used for cases on anti-retroviral therapy (ARV) therapy.  
Treatment was administered 7 days per week, with the injectable drugs being reduced to 3 
times per week when monthly sputum cultures became negative or the patient developed 
side effects.  The injectable drug was stopped when cultures were negative for at least 2 
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successive months or side effects or complications necessitated discontinuance.  Cases 
were discharged to outpatient therapy when their sputum cultures were negative for at least 
3 successive months.  Providing there were no contraindications, all oral medication was 
continued for at least twelve months after the first negative culture had been obtained, with 
a minimum total length of 18 months treatment. 
 
The data from the cases were collected retrospectively using standard data collecting 
instruments. This included age, sex, case type, sputum smear results, case definition (new 
or re-treatment), outcome, and HIV status (if documented).  Also collected was the 
demographic data pertaining to the place of residence of cases at the mine, as well as, the 
details of all hospital admissions.  The confidentiality of individual case information was 
protected and only the clinician in charge of the cases had access to their identities.  
 
3.2.2. Genotyping  
 
All drug-resistant TB isolates were genotyped by IS6110 restriction fragment length 
polymorphism (RFLP) (refer to method section 2.1-A and 2.2-A), spoligotyping (refer to 
method section 2.1-B and 2.2-B) and MIRU-typing (refer to method section 2.1-C and 2.2-
C).  IS6110 genotypes were analysed using Gelcompar II (Version 4.0, Applied Maths, 
BVBA, Kortrijk, Belgium).  The unweighted pair group method with arithmetic mean 
(UPGMA), based on the Dice coefficient was used for cluster analysis with band-matching 
tolerance parameters allowing for a 5% shift in each pattern as a whole and a 0.5% variance 
in individual band positions.   
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Strains with an identical genotype were grouped into clusters reflecting ongoing 
transmission, while strains with unique genotypes were interpreted to reflect either 
acquisition of drug resistance in re-treatment cases or primary resistance in new cases (12).  
  
The katG, rpoB, pncA ,embB and gyrA genes were sequenced using the ABI PRISM DNA 
sequencer to identify non-synonymous single nucleotide polymorphisms (nsSNPs) 
conferring resistance.  Genotypic data was subjected to phylogenetic analysis using the 
neighbour joining algorithm. Bootstrapping was done to establish a degree of statistical 
support for nodes within each phylogenetic reconstruction.  The phylogenetic tree was 
constructed using genotypic data since phenotyping is less accurate and showed high 
variability. 
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3.3. Results 
 
During 2003 a marked increase (140%) in the number of cases with drug-resistant TB was 
noted on a South African gold mine, prompting a molecular epidemiological investigation 
to identify the factors exacerbating this form of disease.  All of the drug-resistant TB cases 
(n=128) diagnosed during the period from December 2002 to November 2005 were 
included in the study cohort.  Routine DST showed that 13 (10%) cases were diagnosed 
with INH mono-resistant TB, 7 (5%) cases were diagnosed with multiple-drug-resistant TB 
and 108 (85%) cases were diagnosed with MDR-TB.  Review of the case folders showed 
that the majority (97%) were male and that the HIV sero-prevalence rate was at least 65% 
(Table 1).  Despite excellent treatment adherence (treatment interruption = 0%), 34% of the 
cases died while on treatment, often as a result of AIDS related causes.  Five of the MDR-
TB cases were diagnosed with XDR-TB.   
 
To determine the M. tuberculosis population structure of the drug-resistant epidemic the 
first available isolate from each case was genotypically classified by MIRU typing and/or 
spoligotyping and IS6110 DNA fingerprinting.  Isolates cultured from cases with mono- 
and multiple-drug-resistant TB showed unique genotypes.  Of these, 11 (55%) were new 
cases, suggesting primary resistance.  A total of 33 different genotypes were identified 
among isolates from MDR-TB cases.  Twenty-seven of these genotypes were unique, of 
which 11 (41%) were cultured from new cases implying primary MDR-TB.  The remaining 
81 MDR-TB isolates could be grouped into 6 clusters, containing between 2-47 cases per 
cluster.  Assuming that each cluster was initiated by a case that acquired MDR-TB, it was 
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estimated that at least 75 of the MDR-TB cases were recently infected with an MDR-TB 
strain through ongoing transmission.  Risk factors for ongoing transmission were not 
evident, possibly due to the over-whelming incidence of HIV co-infection.  However, 
review of the clinical data showed that a large proportion of recently infected MDR-TB 
cases (62%) had a documented previous episode of TB suggesting re-infection with a 
circulating MDR-TB strain (Table 2).  Many of these clustered cases (76%) had a CD4+ 
count of <200, suggesting that cases with a depressed immunity were at a high risk of 
disease progression after recent infection.  
 
This study showed that a large proportion of HIV co-infected cases (66%) were smear 
positive, thereby suggesting that these individuals contributed to the infectious pool.  
However, no association could be found among smear positivity and clustering, implying 
that the pathogenicity of the different bacterial strains may have contributed to the 
transmission of defined strains.  
 
To determine the natural history of the MDR-TB epidemic in this setting, strains from the 
largest cluster (n = 47 patients) were analysed in more detail.  A phylogenetic 
reconstruction based on the nsSNPs conferring resistance to INH, RIF, Emb, PZA and Ofx 
showed that the progenitor MDR strain had acquired resistance to PZA on two separate 
occasions (Figure 2).  These two these strains were subsequently transmitted.  Thereafter, 
Emb resistance evolved independently in a number of different cases.  Following 
transmission, these strains independently evolved resistance to Ofx, ultimately culminating 
with the evolution of three cases of XDR-TB.  Contact tracing showed that 41/45 of the 
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cases (91%) had had contact at either their place of residence, place of work and during 
hospitalisation thereby supporting the notion of ongoing transmission (Figure 2).  
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3.4. Discussion 
 
In 1999 the WHO put forward guidelines, known as the DOTS-Plus strategy to control the 
emergence and spread of drug-resistant TB (13).  These guidelines were designed to 
complement a well functioning DOTS program and were strictly adhered to in the study 
setting from 2001.  To improve TB control, a policy of biannual chest x-ray screening was 
included in the TB control program to actively identify TB cases.  Successful treatment 
outcome targets (set by the WHO) were exceeded for 2.5 years prior to the initiation of this 
study.  Despite these efforts, an alarming increase in the number of cases with drug-
resistant TB and the emergence of XDR-TB was observed.  The increase in the number of 
cases with drug-resistant TB would have been described in classical epidemiological terms 
as an outbreak, possibly as a consequence of the high prevalence of HIV infection, with 
silicosis as a possible additional risk factor or the combination thereof.  Using a 
combination of clinical, epidemiological and molecular data we showed that the drug 
resistant TB epidemic occurred as a result of three factors.  Firstly, the identification of 
drug resistant strains with unique genotypes in cases with no previous documented history 
of treatment with anti-TB drugs, suggested primary drug resistance as a result of infection 
outside of the study setting.  Secondly, the identification of drug resistant strains with 
unique genotypes in cases with a previous documented history of treatment with anti-TB 
drugs, suggested acquisition of drug resistance despite excellent treatment adherence rates.  
However, in these cases we cannot exclude the possibility of re-infection outside of the 
study setting.  Lastly, clustering of strains with identical genotypes showed that the MDR-
TB epidemic was primarily driven by recent transmission of already drug resistant strains.  
From the data available it is not possible to determine whether these MDR-TB strains 
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evolved within the study setting or were imported into the study setting.  If MDR-TB was 
evolving, despite excellent treatment adherence, the mechanism leading to the evolution of 
resistance in these adherent cases warrants further investigation. 
 
In this setting, risk factors for transmission were not obviously evident due to the high 
incidence of HIV co-infection.  However, despite this limitation this study demonstrated 
that a large proportion of patients who had a previous documented episode of TB were re-
infected with a circulating MDR-TB strain.  A previous study has suggested that a prior 
episode of TB may increase the risk of re-infection in a population with a low HIV 
prevalence (14).  This may be particular true in HIV co-infected patients given the fact that 
TB accelerates immune suppression (15) and many of these patients had a CD4+ count of 
<200.   
 
Our findings that a large proportion of the smear positive cases were also HIV+ appeared 
counter intuitive, given that immune suppression has been associated with smear negative 
disease (16).  A possible explanation for our observation was the fact that the diagnostic 
algorithm required 4 sputum samples, thereby raising the chance of detecting O-Auramine 
stained bacilli.  Most importantly, this finding demonstrated that immune suppressed TB 
cases might contribute to ongoing transmission.  This has raised concern over the efficacy 
of the TB control programme, which was unable to identify infectious TB cases prior to 
spreading MDR-TB to their close and susceptible contacts.   
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Our phylogenetic reconstruction of the largest outbreak strain demonstrated sequential 
acquisition of resistance markers, ultimately leading to the evolution of XDR-TB.  This 
may be explained by the fact that all new TB cases were placed on regimen I (HREZ) while 
all re-treatment TB cases were placed on regimen II treatment (HREZS) until drug 
susceptibility tests were available for H and R.  During this diagnostic delay period, TB 
patients with undiagnosed MDR-TB were receiving inappropriate therapy leading to the 
consequential acquisition of additional resistance markers.  Furthermore, these patients 
could have come in contact with susceptible individuals who were hospitalised for illnesses 
other than TB thereby unintentionally perpetuating the drug-resistance epidemic.  These 
results emphasise the importance of the development and implementation of rapid 
diagnostics to minimise the risk of inadvertently placing the patient at risk of developing 
more severe forms of drug resistant disease.   
 
In conclusion this study suggests that TB control measures over and above those 
recommended by the WHO are necessary to control the spread of drug resistant TB in a 
setting with a high incidence of HIV.  Efforts made by the TB control programme in the 
study setting were compromised by an influx of disease thereby emphasising the need to 
ensure well functioning TB control programs in all settings.  A top priority in future TB 
control plans should address clinical and laboratory diagnostic delay more vigorously.  
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Table 1: Patient and clinical data of entire cohort. 
 
N AVG N AVG N AVG N AVG
AVERAGE AGE YEARS 84 43.0 7 43.0 37 42 128 42
N % N % N % N %
SEX MALE 82 97.6% 8 100.0% 37 94.6% 124 96.9%
FEMALE 2 2.2% 0 0.0% 2 5.5% 4 2.9%
CASE TYPE NEW 38 45.2% 0 0.0% 18 48.6% 56 43.8%
RE TREATMENT 49 54.8% 7 100.0% 21 51.4% 72 56.3%
SPUTUM SMEAR POSITIVE 59 70.2% 4 57.1% 31 83.8% 94 73.4%
NEGATIVE 24 28.6% 3 42.9% 5 13.5% 32 25.0%
OTHER 1 1.2% 0 0.0% 1 2.7% 2 1.6%
OUTCOMES RC 19 22.6% 3 42.9% 8 21.6% 30 23.4%
RF 1 1.2% 0 0.0% 0 0.0% 1 0.8%
D 31 36.9% 1 14.3% 12 32.4% 44 34.4%
TO 19 22.6% 0 0.0% 4 10.8% 23 18.0%
A 6 7.1% 0 0.0% 4 10.8% 10 7.8%
ON TREATMENT 8 9.1% 3 37.5% 9 24.3% 20 15.6%
HIV+ HIV- HIV Unk Total
 
 
*International spoligotypes (17) 
Fig. 1.:  DNA fingerprint patterns (IS6110 RFLP, Spoligotype, MIRU type) of drug resistant isolates 
(n=128). 
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Other = Bacteriological confirmation obtained from lymph node, abscess or bone marrow aspiration.  
HIV = Human Immunodeficiency virus, HIV Unk = HIV status unknown 
RC = Treatment completed, bacteriological cure proven, RT = Treatment completed bacteriological cure not proven (n=0),  
RI = Treatment interruption (n=0), RF = Treatment failure, D = Patient died, TO = Transferred Out to other facilities, 
A = Absconded 
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Table 2: Association between clinical and genotypic data of entire cohort. 
 
    Genotype 
 Category HIV status CD4+ count Unique  Clustered 
      
    
H mono 
/Multiple MDR MDR 
       
Treatment History New HIV+   6 7 20 
   HIV-/Unknown  5 4 8 
  Re-treatment HIV+  1 9 30 
   HIV-/Unknown  2 7 13 
            
 New HIV+ <200 2 3 16 
   HIV+ >200 - - 2 
  Re-treatment HIV+ <200 1 3 19 
   HIV+ >200 - - 9 
            
Smear Positive HIV+   3 10 38 
   HIV-/Unknown  6 11 14 
  Negative/Extra-pulmonary HIV+  4 6 12 
   HIV-/Unknown  1 - 7 
            
 Positive HIV+ <200 2 4 28 
   HIV+ >200 - 2 8 
 Negative/Extra-pulmonary HIV+ <200 1 2 7 
  HIV+ >200 2 1 3 
       
Deaths    1 8 29 
       
 
HIV = Human Immunodeficiency syndrome, HIV+ = HIV sero positive, HIV - = HIV sero negative, Unknown = HIV status unknown 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 79
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.: Phylogenetic history of the largest outbreak MDR-TB cluster.  
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Legend: The phylogentic tree was constructed using the neighbour joining algorithm (18). The gene and 
the mutation conferring resistance are indicated at the node where they occurred.  Bootstrap values are 
shown at internal nodes in brackets.  Each case is represented by a number at the end of each branch with 
the corresponding dates representing the time of MDR-TB diagnosis.  Contact tracing data is indicated for 
each case where PR indicates sharing the same residence, S08 denotes the mine shaft were the case worked 
and HP indicates whether the case was hospitalised at the same time as another member of the cluster was 
being treated from MDR-TB.  The three XDR-TB cases are indicated in bold. Genetic data for two cases 
was not available. 
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Chapter 4 
 
The dynamics of drug resistant Mycobacterium tuberculosis 
strains in the Western and Southern Cape of South Africa 
 
My contributions: 
• Study design. 
• Genotyping by IS6110 RFLP. 
• Interpretation of data. 
• This chapter includes data that formed part of a published paper: An outbreak of drug 
resistant Tuberculosis caused by a Beijing strain in the Western Cape, South 
Africa.2006. International Journal of Tuberculosis and Lung Disease. R. Johnson, 
R.M. Warren, O. Strauss, A.M. Jordaan, A.A. Falmer, N. Beyers, H.S. Schaaf, M. 
Murray, K. Cloete, P.D. van Helden, T.C. Victor. 
• This chapter includes data that was included in a manuscript, submitted for peer 
review in October 2007 to Journal of Clinical Microbiology: Spread of a low-fitness 
drug resistant M.tuberculosis strain in a setting of a high HIV prevalence. O. Strauss, 
R.M. Warren, A.M. Jordaan, E.M. Streicher, M. Hanekom, A.A. Falmer, H. Albert, 
A. Trollip, E. Hoosain, P.D. van Helden, T.C. Victor.  
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4.1. Introduction 
 
South Africa is currently listed as one of the high-burden countries for drug resistant 
tuberculosis (TB) (25). MDR-TB was first identified in the Western Cape in 1982, 
subsequently rates have increased but has remained lower compared to other provinces in 
the country (24).  The concern over MDR-TB is particularly valid especially with the 
emergence of extreme drug resistant TB (XDR-TB) (6). Based on strains that were stored 
since 2005 at the South African National Health Laboratory Services (NHLS), XDR-TB 
was already present in all nine provinces (11). Currently, it is estimated that 600 cases per 
year will be diagnosed with XDR-TB in South Africa (26).  The province with the 
highest number of XDR-TB cases is Kwa-Zulu Natal, possibly as a result of high HIV 
prevalence and/or due to low TB cure rates. In the Western Cape TB cure rates have 
exceeded 70%, and is currently one of the provinces with the lowest number of XDR-TB 
cases. 
 
The application of molecular studies can aid in unravelling and understanding the 
dynamics of drug resistant TB strains circulating within communities. The polymorphic 
GC-rich sequence (PGRS) (3), multiple interspersed repetitive units (MIRU) (15), 
spoligotyping (8), IS6110 restriction fragment length polymorphism (RFLP) (17), and 
other PCR-based methods (9) are examples of various genotyping methods that have 
been developed as molecular epidemiological tools. Even though each method has its 
limitations, these methods provide information based on the type of study and the 
question that is asked. RFLP and MIRU-VNTR typing are the most appropriate 
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genotyping methods for discriminating between strains such as the Beijing family, while 
MIRU analysis can also be used to determine the phylogenetic relationship of strains 
within different Beijing families as well as low copy clade families (10). Since the 
spoligopatterns of low copy IS6110 strains are less stable than the IS6110 RFLP patterns, 
spoligotyping can be used as a secondary typing method for these low copy clade strains 
(2). However, RFLP still remains the gold standard, and was central in the identification 
of drug resistant M.tuberculosis outbreaks in hospitals (5,13), prisons (16) and 
communities (18,19,22). 
 
The aim in this study is to investigate the dynamics of drug resistant strains in three 
different regions in South Africa.  
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4.2. Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.: Map showing the incidence of TB as well as the HIV prevalence in the total population during 
2006. 
 
 
 
**Western Cape
Eastern Cape
Eastern Cape: TB incidence = 705/100 000 pa1 ;  HIV prevalence = 30%2
* Western Cape: TB incidence =  1030.7/100 000 pa1 ; HIV prevalence = 10%2 
**
*
2[HIV Household Survey 2002] Shisana O, Principal Investigator. Nelson Mandela/HSRC Study 
of HIV/AIDS - South African National HIV Prevalence, Behavioural Risks and Mass Media 
Household Survey 2002. Cape Town: Human Sciences Research Council; 2002. 
http://www.hsrcpublishers.co.za/hiv.html hh
1[DOH TB] Department of Health (TB section). Pretoria. http://www.doh.gov.za/tb/
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4.2.1. Study Design and Treatment features 
 
Re-treatment cases are more likely to develop drug resistance and MDR-TB, which 
makes this group a very high-risk TB group. Sputum were routinely collected from this 
high-risk group and sent to the NHLS for drug susceptibility testing. All drug resistant 
isolates were then referred to Stellenbosch University for further molecular analysis. 
Genotypic data were compiled in a longitudinal reference database along with clinical 
and socio-economic information of all of the cases. The results presented in this study 
only reflect the fingerprint data and not a comparison between clinical and socio-
economical factors. 
 
4.2.2. Study Settings 
Study 1: Boland-Overberg and Southern Cape-Karoo (BOKS) 
 
The TB incidence rate in the Western Cape region for 2006 was 1 030/100 000 per year 
and the HIV prevalence for the total population in this province was 10%. M.tuberculosis 
isolates were collected from re-treatment and treatment failure cases from 72 clinics 
within two of the four health districts; Boland-Overberg and Southern Cape-Karoo 
(collectively called BOKS) region between January 2001 to February 2006 in the 
Western Cape province. Initially, spoligotyping was used to genotype only the first 
isolate taken from cases having drug resistant TB (n=1159) and thereby group these 
isolates into the different strain families (14). To further investigate the distribution of the 
selected M.tuberculosis genotypes, IS6110 RFLP (for full description of method, refer to 
method section 2.1 A and 2.2 A) was done.
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Fig.2.: Diagram of sample allocations. 
 
Reference database 
Beijing 
n = 182
F11
n = 95
LCC
n = 65
Spoligotyping
n=1159
IS6110 RFLP
n = 359
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Study 2: XDR and Pre-XDR isolates 
 
The second study involved 143 isolates collected (between November 2006-August 
2007) from cases that were diagnosed with pre-XDR (MDR with additional resistance to 
either a flouroquinolone or one of the three injectable drugs: amikacin, kanamycin and 
capreomycin) and XDR-TB (MDR with additional resistance to a fluoroquinolone and 
one or more of the three injectable drugs: amikacin, kanamycin and capreomycin) in the 
Western Cape. Positive cultures needed for RFLP was available for only 139 isolates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3: Diagram of sample allocations. 
 
Sputum collected from 143 cases
NHLS = DST
139 culture positive isolates from 
139 cases for IS6110 RFLP
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Study 3: Eastern Cape 
 
Sputum were collected from 127 re-treatment cases at 6 different clinics in the Port 
Elizabeth and Uitenhage Metropolitan region of the Eastern Cape. Routine culture drug 
susceptibility testing was done on all isolates. A total of 127 culture positive isolates were 
referred for IS6110 RFLP analysis. Only 121 isolates had completed fingerprinting as 
well as drug resistant mutation data available for further analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Diagram of sample allocations. 
NHLS = DST
121 randomly selected for 
IS6110 RFLP
127 isolates for 
IS6110 RFLP
55 Drug resistant 
isolates 
66 Drug susceptible 
isolates 
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4.2.3. Definitions based on IS6110 RFLP 
 
Genotype   : Genetic composition of strain. 
Family : Group of strains displaying similar genotypes, which 
derives from a common progenitor. 
Super family/clade : Internationally assigned according to the classification of 
groups of strain families based on genetic similarities. 
Cluster : A group of two or more TB cases with isolates displaying 
identical IS6110 RFLP genotypes that have been in recent 
contact. 
Small cluster : Group of <10 cases with isolates that have identical RFLP 
genotypes. 
Large cluster : Group of >10 cases with isolates that have identical RFLP 
genotypes. 
Unique : A strain with a specific genotype resembling no other 
genotype within a setting. 
Outbreak : Is a sudden increase of drug resistant strains above the 
expected  baseline for a specific region (fig.5). 
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Fig.5.: A schematic view of an outbreak. 
 
4.2.4. IS6110 RFLP Analysis  
 
The analysis software, Gelcompar is suited for analyzing DNA fingerprints and storage 
of these fingerprints in a database. Figure 6 is an example of TB strains characterized by 
IS6110 RFLP analysis. The similarity between different IS6110 RFLP patterns are 
calculated by the Dice coefficient with 5% tolerance parameters for band matching in 
each pattern as a whole and 0.5% variance in individual band positions. These patterns 
are then grouped according to their similarities by the unweighted pair group method 
with arithmetic mean (UPMGA) in the form of a dendogram with similarity matrix on the 
far left. Each isolate is indicated according to their corresponding isolate number for easy 
identification. Along with the isolate number, the ‘Family’ as well as ‘Cluster’ number 
are assigned. Strain family names are usually depicted with an “F” for family followed by 
the name assigned to the family. Based on the IS6110 insertion sequence, different 
groups of strains exist within the same strain family (e.g. Beijing), which are also given a 
Outbreak
Baseline
Intervention
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name for easy identification. This is known as the IS6110 number but it is usually 
referred to as the cluster name. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6.: Gelcompar (Applied Maths, Kortrijk, Belgium)-generated dendrogram of percentage similarity as 
calculated by Dice coefficient.  
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Legend: A dendogram was constructed using the UPGMA algorithm, which is based on the Dice 
coefficient. Family assignments as well as cluster analysis were according to tolerance parameters (refer to 
chapter 2). On the extreme right, the “family” and “cluster” names are usually inserted. Within the 
dendogram, a cluster is usually presented as a single line i.e. F140 with cluster 330 (n=3).  
 
Table 1 is an example of different strain families that are members of the same super 
family. The super family known as “X1” consist of all low copy clade (LCC) strains with 
<5 IS6110 insertions (table 1). 
 
Table 1: Summary of different strain families and examples of clusters within the strain families. 
local Family name Super family* 
F29, F31 Beijing 
F11, F9, F13 Latin-American-
Mediterranean (LAM) 
F110, F120, F140, F150 X1 
*International recognized family 
 
 
4.2.5. Quality Control 
 
Parameters that allow for band shifting have a significant influence on fingerprinting 
analysis. As observed in figure 7, an arrow indicates the difference between two DNA 
patterns of two different typical Beijing isolates by one band shift. Therefore, it is 
important to apply parameters to ensure optimal strain analysis as well as quality control 
of the analysis.  
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Fig.7.: Differences between IS6110 patterns of a typical and atypical Beijing genotype. 
Legend: The red box indicates the characteristic DNA bands, which is generally not present in the atypical 
Beijing strains. Also, note the two clusters; 208 and 6004, which are almost identical except for a single 
band shift (arrow). 
 
With IS6110 RFLP, two different strain lineages can be identified within the Beijing 
family. These strains can be differentiated by the characteristic IS6110 DNA patterns 
(fig.7) or by the presence (typical) or absence (atypical) of an IS6110 insertion within the 
NTF region. Phylogenetic analysis shows that the atypical Beijing strains are more 
ancient than the typical strains, which have recently evolved. 
 
 
 
 
 
.
.
.
.
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4.3. Results 
(Results from each study will be reported separately) 
 
4.3.1. Study site 1: Boland/Overberg-Southern Cape/Karoo (BOKS) 
 
Among the spoligotype patterns (n = 1159), three dominant strain families were present 
(fig. 8) of which the Beijing strain family was the most dominant drug resistant family. 
Based on the spoligotype data, a significant increase [p=0.0116] in the Beijing strain 
family was observed during this study period (fig.9).  
 
31%
12%
25%
32%
Beijing
F11
LCC
other
 
Fig. 8.: The three dominant drug resistant strain families according to spoligotyping. 
Legend: Three drug resistant strain families were prominent but Beijing was characterized among the 
majority of drug resistant cases. The group labelled as “other” consist of unique drug resistant strains as 
well as drug resistant families that are in the minority of the total isolates.   
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Fig.9.: Ratio of the three drug resistant strain families. 
Legend: The Beijing strain increased over the years and remained dominant during this study period. 
 
To further understand the reason responsible for the increase in the Beijing strain family, 
IS6110 RFLP was used to type randomly selected Beijing isolates (n=182). The results 
showed that 92% were identified as typical Beijing and 7.7% were atypical Beijing 
strains.  Fourteen clusters were identified among the typical Beijing isolates of which 
cluster 220 (57/182[31%]) was overrepresented (fig.10).  During this study period, an 
MDR outbreak of cluster 220 was identified among children attending a high school in 
Cape Town (7). During that outbreak, a rapid PCR-based method was developed to 
uniquely identify cluster 220 isolates. This method was used by R. Johnson (from the 
Division of Molecular Biology and Human Genetics, Faculty of Health Science, 
Stellenbosch University) to identify cluster 220 strains amongst all the Beijing isolates 
(n=364) characterized by spoligotyping in this study. The results revealed that during 
2001-2006, cluster 220 (147/364[40%]) strains increased and it was widespread in the 
region. Samples collected in 2003 were excluded from analysis due to under sampling as 
well as 2007 since sample collection is not completed. DST of cluster 220 isolates 
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revealed that 36% (53/147) were INH mono resistant and 63% (93/147) were MDR, 
indicating that the incidence of this strain was due to a combination of acquisition and 
transmission. Thus far no drug susceptible cluster 220 has been found in the region (A 
manuscript concerning cluster 220 is currently in preparation by R Johnson). 
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Fig.10.: Clusters within the typical Beijing drug resistant strain family. 
Legend: Each cluster is represented by the percentage of isolates that are either INH mono resistant or 
MDR.  Cluster 220 is the most prevalent among all typical Beijing clusters. 
 
Of the limited number of randomly selected LCC isolates, 88% were clustered in this 
region whereas most of the F11 strains were identified as uniques (60%). 
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4.3.2. Study site 2: Pre-XDR and XDR study 
 
Of the 139 culture positive isolates, RFLP data of 49 (62% XDR and 38% Pre-XDR) 
isolates was available for analysis. However, Similar to study site 1, the typical Beijing 
genotype was dominant (49%[24/49]) among these isolates. None of the cases infected 
with atypical Beijing strains were diagnosed with pre-XDR-TB, however pre-XDR was 
predominantly diagnosed in cases infected with typical Beijing strains (fig.11). Among 
the typical Beijing group of strain, four genotypes were shared between 57% of cases.  
 
 
 
 
 
 
 
 
 
 
 
Fig.11.: Distribution of Pre-XDR and XDR strains among Beijing isolates 
Legend: Pre-XDR and XDR isolates are grouped according to the IS6110 family. 
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4.3.3. Study site 3: Eastern Cape  
 
One hundred and twenty-one randomly selected isolates were fingerprinted by IS6110 
RFLP of which 55 isolates were drug resistant and 50 of these isolates were MDR-TB.  
Atypical Beijing genotypes were characterized among 62% (34/55) of the drug resistant 
isolates and were mostly clustered, indicating ongoing transmission (Fig.12). Additional 
sequence analysis of the rpoB gene of the atypical strains indicated that the high fitness 
cost rpoB516 mutation was overrepresented in the atypical strains and that cases infected 
with atypical strains are associated with HIV co-infection. 
 
 
Fig.12.: Strain distribution in the Eastern Cape setting 
Legend: Most isolates had the atypical Beijing genotype, which consisted of 3 distinct clusters with sizes 
varying from 3 – 16 cases. M.tuberculosis strain families are shown as F0, F11, F14, F15, F19, F23, F29, 
F31, F140 of which F29 and F31 are typical Beijing and atypical Beijing strains, respectively. 
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4.4. Discussion 
 
In recent years, molecular epidemiological methods have been applied to numerous 
studies to document the transmission dynamics of both drug susceptible and resistant 
M.tuberculosis strains within a given population, thereby providing new insights into TB 
epidemiology (20). This study indicates that transmission was largely the cause of the 
drug resistant epidemic in all three settings. This is in contrast to the findings obtained by 
drug resistance surveillance studies, which reported that acquired resistance is more 
common than primary (transmitted) drug resistance (4).  
 
It is important to note that the 3 different studies cannot be compared due to the following 
reasons: 1) each of these studies was done during different study periods and 2) at least 
two years of study is necessary to obtain significant epidemiological data. Our 
conclusions therefore, are based on observations in each separate study setting. However, 
it must be noted that the aim of this study was not to report on the incidence of drug 
resistance but rather what factors drive the epidemic. We believe that a longitudinal study 
would be more informative than drug surveillance studies in a high incidence setting 
where most drug resistant cases are due to transmission. Therefore, cases of transmission 
would not be underestimated. The contribution of transmission as well as acquisition of 
drug resistance to the epidemic will aid in the subsequent selection of an appropriate TB 
control strategy designed to reduce the MDR-TB rates. Indeed, molecular epidemiology 
may provide more information about an epidemic therefore aiding in developing a TB 
control strategy suited for the epidemic.  
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Of the three dominant drug resistant strains that we identified in the BOKS region during 
2001 to 2006 (14), the Beijing family remained the dominant genotype. F11 is a 
prominent member of the LAM family, which has been previously identified in the 
Western Cape (21,23). The dominance of certain strain families in different geographical 
regions might be due to certain properties that allow these groups of strain families to be 
more virulent than others. Alternatively, an evolutionary investigation of the strain 
families might reveal that these families were present in the setting over a long period, 
which explains their high frequency of cases.  
 
From earlier studies, there is evidence of hyper-virulent strains that are highly 
transmissible such as the drug resistant Beijing cluster 220 (7). Conclusive evidence from 
our data indicated that the hyper-virulent cluster 220 strain was responsible for the 
increasing Beijing frequency in the Boland-Overberg and Southern Cape-Karoo regions. 
The contribution of cluster 220 to the MDR-TB rates within these communities is 
significant and therefore cluster 220 is a huge problem and cannot be contained by the 
TB control program. Since the genome of M.tuberculosis has been sequenced, it is now 
possible to uncover genomic differences in these drug resistant strains that might lead to 
hyper- virulence. Additional methods include whole genome sequencing, proteomics and 
microarray analysis to identify these genomic properties. 
 
The prevalence of Beijing in the Eastern Cape was due to an atypical Beijing genotype, 
which contradicts the perception that atypical Beijing genotypes are assumed to have a 
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lower fitness than typical Beijing genotypes. Atypical Beijing strains are generally 
attenuated and usually not associated with transmission (12). Interestingly in this study 
setting, the majority of drug resistant atypical isolates showed the presence of the high 
cost rpoB516 mutation, conferring rifampicin resistance. We suggest that HIV co-infection 
posed as a risk factor for the spread of atypical Beijing genotypes in the Eastern Cape. 
This was supported by our observations in the Western Cape where the HIV prevalence is 
low and the frequency of cases infected with the atypical Beijing genotype was much 
lower (7.7% among Beijing strains).  
 
It is interesting to note however, that XDR cases in the Western Cape province (43% 
infected with Beijing strain) and in a mine setting in the northern province (F1 : n=2 ; 
F11 : n=1 ; F13 : n=1; F140 : n=3) were infected with strains that were different to the 
XDR-TB KZN strain that caused the deaths of 52 immunocompromised patients at 
Tugela Ferry (6). Therefore different strains have the ability to evolve into XDR-TB. We 
do not know, as yet, why only certain strains acquire more resistance readily than others, 
especially in the presence of an excellent TB control program, which exceeds the TB cure 
rate target set by the WHO.  
 
It is possible that geographic evolution may have contributed to the genotypic diversity of 
M.tuberculosis strains within different geographic settings. Ahmed et al (1) suggested 
that specific genomic deletions and synonymous substitutions that were selected against 
host and environmental stresses, may have been the cause for such changes. We 
acknowledge that the evolutionary clock of the molecular markers have a significant 
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impact on our interpretation of molecular epidemiology. Therefore, our interpretation of 
our data is based on the molecular methods, which was selected for analysis.  
 
This study highlights the importance of drug susceptibility testing in all cases particularly 
in vulnerable populations. To prevent transmission of MDR-TB, better infection control 
need to be established. However, prevention of acquiring drug resistance might be the 
main root to the problem, thereby indicating the need to improve control programs so that 
they include rapid detection of drug resistance.  
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